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Development of drug delivery systems (ie. nanocarriers) with controllable 
composition, architecture, and functionalities is heavily investigated in the field of 
drug delivery in order to improve clinical interventions. Designing drug nanocarriers 
which possess targeting properties is critical to enable them to reach the intended site 
of intervention in the body. To achieve this goal, the surface of drug nanocarriers can 
be modified with targeting moieties (antibodies, peptides, etc.) addressed to cell 
surface molecules expressed on the diseased tissues and cells. If these molecules are 
receptors capable of internalizing bound ligands via endocytosis, targeting can then 
enable drug transport into cells or across cellular barriers in the body. Yet, addressing 
  
nanocarriers to single targets presents limited control over cellular interactions and 
biodistribution. Since most cell-surface markers are not exclusively expressed in a 
precise site in vivo, high affinity of targeted nanocarriers may lead to non-desired 
accumulation in regions of the body associated with low expression. Modification of 
nanocarriers to achieve combined-targeting (binding to more than one cell-surface 
receptor) may help modulate binding to cells and also endocytosis, since cell 
receptors possess distinct functions and features affecting these parameters, such as 
their expression, location on the plasmalemma, activation in disease, mechanism of 
endocytosis, etc. Further, targeting nanocarriers to multiple epitopes of the same 
receptor, a strategy which has never been tested, may also modulate these parameters 
since they are highly epitope specific. In this dissertation, we investigate the effect of 
targeting model polymer nanocarriers to: (1) multiple receptors of similar function 
(intercellular-, platelet-endothelial-, and/or vascular- cell adhesion molecules), (2) 
multiple receptors of different function (intercellular adhesion molecule 1 and 
transferrin receptor), or (3) multiple epitopes of the same receptor (transferrin 
receptor epitopes 8D3 and R17). Binding to cells, endocytosis within cells, and 
biodistribution in mice were tested. Results indicate that combination targeting 
enhanced performance of nanocarriers with regard to these three parameters as 
compared to non-targeted nanocarriers and modulated their outcome relative to 
single-targeted nanocarriers. This modulation was observed as enhanced, 
intermediate, or diminished interaction with cells, accumulation in particular organs, 
and specificity for diseased sites relative to single-targeted nanocarriers. These results 
were general to strategies 1-3 and were difficult to foresee a priori due to the 
  
complex nature of said interactions. Importantly, outcomes depended on the 
multiplicity (dual- vs. triple-targeting) and/or combination of affinity moieties 
displayed on the nanocarrier surface, as well as the physiological/pathological state of 
cells and tissues. Modulation of the delivery of a model therapeutic cargo in mice 
relative to single-targeted nanocarriers demonstrated the potential of these strategies 
to control the biodistribution of therapeutic agents. Therefore, these findings illustrate 
that combination-targeting enables modulation over cellular interactions and 
biodistribution of nanocarriers, which may aid the development of nanocarriers 
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Section 1: Introduction and Overview                                                                                                                                                                  
1.1. Problem Description and Motivation 
Drug delivery systems designed to target pharmaceutical agents to the intended site 
in the body can improve many current limitations of medical treatments by 
enhancing or optimizing accumulation at the intended site of activity and limiting 
accumulation in off-target areas.1-3 A promising strategy to achieve targeting of drug 
delivery systems (i.e. nanocarriers) is to couple affinity moieties (e.g. antibodies or 
their fragments, peptides, aptamers, etc.) which recognize particular molecules 
present on the surface of cells.1-3 This approach can enhance drug accumulation in 
specific organs, tissues, cells, subcellular compartments, or across cellular barriers, 
and is being heavily investigated for numerous diseases including cardiovascular, 
metabolic, pulmonary, neurological, and inherited disorders, as well as cancers, 
infectious diseases and many other applications.1-3   
   
 Despite these advantages, targeting nanocarriers to single cell-surface 
markers oftentimes results in suboptimal accumulation and lack of precise control of 
nanocarriers in the body. For example, although targeting can improve nanocarrier 
delivery at the target site, most targeted nanocarriers also accumulate in clearance 
organs, such as the spleen and liver, resulting in an improved (over non-targeted) but 
still suboptimal outcome.4 Due to this, strategies which improve accumulation in 
other organs are highly beneficial,5,6 and certain therapeutic approaches may require 
delivery to multiple cell types (e.g. angiogenic blood vessels and tumor cells for 
cancer therapy)7 which may not all adequately express the target molecule. Further, 
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control of the biodistribution is limited in part because molecules used as targets are 
rarely expressed solely in a single cell type or tissue, making it difficult to maximize 
selectivity for precise niches in vivo.3,4 Expression of a target within a population of 
cells is heterogeneous (i.e. spatially and temporally), which can limit the fraction of 
cells susceptible to targeting.3,4 Accessibility of the selected target molecule may be 
restricted by its location on the plasmalemma, predominance of isoforms lacking the 
target epitope, or altered molecular conformation, and all of these characteristics 
may be affected by the physiology or pathophysiology of the local environment and 
severity of the disease state.3,8 In addition, the factors affecting targeting are complex 
and intertwined, such that altering one parameter (e.g. increasing affinity for the 
target molecule) can produce several effects which may or may not be intended, e.g. 
increasing binding at the target site while simultaneously increasing binding at off-
target sites, inducing endocytosis, etc.3,9 Thus, although targeting to single cell-
surface molecules can be beneficial, in many circumstances the result is not ideal 
and often cannot be corrected by optimizing nanocarrier design parameters (e.g. 
ligand valency, size, shape, etc.) due to the dynamic nature of the interaction. 
Strategies which improve control over targeting can help to optimize nanocarrier 
delivery for particular applications. From these points of view, targeting nanocarriers 
to multiple, rather than single, cell-surface molecules (namely combination 






1.2. Our approach  
Combination targeting is an emerging approach which holds promise to enhance 
and/or more precisely control delivery of nanocarriers. It exists in nature with regard 
to infectious pathogens10 and cells of the immune system11 which interact with 
multiple receptors to adhere and/or induce transport into cells or across cellular 
barriers. Combination targeting strategies have recently arisen in targeted drug 
delivery,7,12-14 providing new approaches to enhance and optimize specificity and 
selectivity of nanocarriers for the target site. For example, the overexpression of 
multiple molecules on the surface of cancer cells has been exploited to enhance 
tumor selectivity of liposomes by triggering internalization only in cells expressing 
both molecules.14 In another study, multi-targeting enhanced accumulation of 
mesoporous silica nanoparticles in both angiogenic blood vessels and tumor cells by 
addressing multiple receptors in those cells.7 Yet, such studies are limited to a 
particular scope or drug delivery system and in many cases the effects of targeting 
molecules of different or similar function have not been examined systematically in 
both cell cultures and in vivo models. In the case of polymer nanocarriers, 
combination targeting studies are mainly limited to cellular binding studies of 
receptors with similar function, leaving unknown the effects on endocytosis and 
biodistribution or the effects of targeting molecules with different functions. 
Targeting nanocarriers to multiple epitopes of the same molecule or receptor may 
also provide advantages with regard to enhancing and/or controlling accumulation. 
For example, binding at a certain epitope may alter the molecular conformation of 
the target to enhance accessibility of a second epitope15 or it may enable targeting of 
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a greater or lesser number of molecular isoforms of the target present on a single cell 
type or in different tissues. However, such a strategy has never been explored in the 
context of nanocarriers.  
 
 The global hypothesis of this dissertation is that combination targeting can be 
utilized to modulate and control the binding, internalization, and/or the 
biodistribution of polymer nanocarriers addressed to three different categories of 
cell-surface targets: 1 multiple receptors with similar functions, 2 multiple receptors 
with different functions, and 3 multiple epitopes of the same receptor. 
 
 Investigation of these strategies in cell cultures and in vivo is necessary to 
develop general knowledge of combination targeting with respect to critical 
parameters of drug delivery, including binding to cells, accumulation on the cell 
surface versus intracellular compartments, performance in physiological versus 
diseased conditions, distribution of nanocarriers in the body, and the resultant impact 
on the delivery of the associated pharmaceutical “cargo.” The reductionist 
environment of cell cultures provides a useful system for analyzing the effect of 
targeting on drug delivery parameters (e.g. binding, internalization, etc.). Yet, in vivo 
testing in laboratory animals is essential to affirm results in the context of the true 
physiology of the body, where structural features or regulation of the target receptors 
may vary in different tissues, and additional physiological factors (e.g. physiological 
shear stress from fluid flow,16,17 clearance from the circulation by immune cells,18 




 In the next section (Section 2), background is provided on the many 
challenges which nanocarrier-based drug delivery systems aim to address, as well as 
targeting and transport of nanocarriers targeted to single cell-surface molecules and 
the nascent field of combination targeting. The methods used to conduct the studies 
are described (Section 3), followed by the results and discussion (Section 4), and the 
overall conclusions and potential future directions of the research in light of the 
presented findings (Section 5). 
 
1.3. Significance and Novelty  
The significance of the studies presented in this dissertation is that they expand 
current knowledge or provide the first data on combination targeting of polymer 
nanocarriers to multiple receptors or epitopes at the levels of binding and 
internalization in cells, distribution in the body, and delivery of associated 
therapeutic cargo. The receptors investigated are intercellular adhesion molecule-1  
(ICAM-1),21 platelet-endothelial cell adhesion molecule-1 (PECAM-1),21 vascular 
cell adhesion molecule-1 (VCAM-1),21 and the transferrin receptor (TfR).6 These 
receptors are highly relevant for drug delivery due to their use in targeting numerous 
therapeutic and diagnostic agents in applications including cancer, atherosclerosis 
and other cardiovascular disorders, multiple sclerosis, inflammation, arthritis, stroke, 
graft rejection, thrombosis, genetic lysosomal storage disorders, or neurodegenative 
disorders.22-47 In addition, most previous studies on combination targeting focused 
on binding of micro- rather than nano- carriers to cells with relatively few studies 
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examining internalization within cells, or biodistribution in vivo. This dissertation 
builds on this gap by evaluating nanocarrier internalization and biodistribution in 
addition to cell binding using nanoscale carriers which are relevant for most in vivo 
applications and for endocytic transport via most known mechanisms. 
 
 Existing knowledge of combination targeting of molecular receptors with 
functions which are related or similar (i.e. cell proliferation, adhesion, 
transmigration, pathogen detection, nutrient metabolism, etc.) is expanded to explore 
novel or scarcely examined aspects of multi-targeting cell adhesion molecules 
(CAMs), involved in cell adhesion and transmigration of leukocytes to sites of 
inflammation. In terms of targeting, combination targeting of nanocarriers to 
multiple Ig-like CAMs is examined for the first time using different combinations 
and multiplicity of affinity moieties (i.e. dual or triple-targeting) directed to 
intercellular-, platelet-endothelial-, and/or vascular- cell adhesion molecules (Section 
4.1). Effects of this form of multi-CAM-targeting on the biodistribution and on 
delivery of biological therapeutics are also examined. In addition, we examine 
effects of multi-CAM-targeting on nanocarrier internalization using receptors 
associated with the same endocytic pathway (ICAM-1 and PECAM-1 associated 
with CAM-mediated endocytosis) versus receptors associated with different 
endocytic pathways (ICAM-1 and VCAM-1 associated with CAM- and clathrin-
mediated endocytosis, respectively). In the next section (Section 4.2), knowledge of 
combination targeting of molecular receptors with different function is expanded to 
include ICAM-1 and transferrin receptor, which are involved in leukocyte adhesion 
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and transmigration versus iron transport, are upregulated or remain stable in 
response to disease, and are involved in CAM- versus clathrin-mediated endocytosis, 
respectively. These differences are unique from most prior combination targeting 
strategies which examined receptors involved in similar functions (cell adhesion) 
and endocytic pathways (clathrin-mediated endocytosis), and these factors can 
significantly affect nanocarrier targeting and internalization. In the final section, we 
examine the novel approach of targeting nanocarriers to multiple epitopes of the 
same receptor. Such a strategy can provide a new means to alter the avidity for the 
target receptor, and as a result modulate nanocarrier targeting performance. This 
approach may be particularly useful in circumstances where varying other targeting 
parameters (i.e. nanocarrier size, ligand valency, etc) leads to unwanted effects. 
 
 Overall the findings in this dissertation illustrate the promise of combination 
targeting as a strategy for drug delivery which enables control over cellular 
interactions and biodistribution of nanocarriers. Combination targeting, whether 
directed to multiple receptors of similar or different functions, or to multiple 
epitopes of the same receptor, allows modulation of drug delivery parameters 
including binding to cells, endocytosis, and biodistribution. Importantly, the 
resultant behavior can not be predicted a priori and requires experimental evaluation 
both in cell cultures and in vivo. Yet, combination targeting provides a useful 
approach for the development of nanomedicines because, rather than having to 
discover new targets, it allows the drug delivery system to be adapted to the needs of 
the therapy by combining properties of existing targets which can be optimized. 
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Section 2: Background 
2.1. Drug Delivery: Purpose and Challenges 
The overall purpose of drug delivery is to optimize the pharmacokinetics of agents 
administered into the body for an intended application. These agents can be used for 
prophylactic, therapeutic, or diagnostic applications, and are designed to prevent the 
occurrence of disease, determine whether disease is present, or treat disease, 
respectively. Therapeutic or prophylactic agents are biologically active substances. 
These can be small molecules, typically low molecular weight organic or inorganic 
molecules produced by chemical synthesis. In addition, the use of biologicals for 
prophylaxis or therapy has rapidly expanded. These are macromolecules derived 
from living systems, such as cell cultures, bioreactors, ascites animals, etc., and 
include proteins (antibodies,48 enzymes,49 etc.), nucleic acids (aptamers,50 siRNA,51 
plasmids,52 etc.), and carbohydrates (vaccines,53 immunotherapies,54 etc.). Additional 
types of agents are represented by metals,55 radioisotopes,56 fluorescent markers,57,58 
microbubbles,59 etc., which are utilized to provide contrast for imaging modalities, 
such as computed X-ray tomography (CT), magnetic resonance imaging (MRI), 
optical coherence tomography, positron emission tomography (PET), ultrasound,  
etc. Yet, oftentimes the efficacy of all of these agents and their safety is impaired or 
suboptimal due to pharmacokinetic limitations. As a consequence, treatment of many 
diseases would be greatly improved by more effective drug delivery strategies.6,60,61  
 
 Drug delivery science is applied to most, if not all, aspects of 
pharmacokinetics. In general terms, pharmacokinetics is the study of the 
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accumulation and evolution of pharmaceutical agents the blood, tissues, and organs 
over time.62 This typically involves the absorption of the agent into the bloodstream, 
circulation in the blood, distribution from the blood to tissues, metabolism of the 
agent in tissues, and excretion from the body.62,63 Regarding absorption, a main goal 
of drug delivery is to improve the solubility of agents which are not soluble or 
poorly soluble in physiological fluids and, therefore, cannot be absorbed.64 Agents 
which are absorbable should be stable in the presence of blood components, and also 
must remain in the circulation long enough to achieve an adequate concentration at 
the target site. This can be affected by interaction with blood components (e.g. 
opsonization)65 and can result in premature clearance from the circulation, even in 
cases where delivery systems are endowed with “stealth” properties.66 To improve 
the distribution of agents, which is another goal of paramount importance, drug 
delivery strategies aim to increase the agent concentration at the intended site of 
activity (enhancing its bioavailability) and to minimize distribution in areas of the 
body where the agent is not needed (reducing potential toxicity and waste of the 
agent).1,2 Improving bioavailability can help create new treatments either by 
allowing agents to reach sites in the body which were previously inaccessible67 or by 
increasing the bioavailability of an agent to the point where it is effective for a 
particular application.1 For example, the vascular endothelial lining of blood vessels 
can allow a certain amount of transport into tumor areas,68 but can also limit 
transport from the bloodstream to other tissues. This is most evident in the brain, 
where the blood-brain barrier restricts transport of most substances to the brain 
parenchyma.67 Another major cellular barrier is the epithelial lining of the 
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gastrointestinal (GI) tract where free transport of substances is also restricted, 
limiting delivery of agents orally.69 Biological barriers of drug delivery are also 
present in other organs including the skin,70 lungs,71 and mucosal linings throughout 
the body.72 At the cellular level, the plasma membrane or the membranes of 
intracellular compartments represent additional barriers to drug penetration.73 
Consequently, targeting and internalization into cells can improve the distribution of 
agents to the site of activity. Reducing toxicity is also very important74 as less or, 
ideally, no harm should result from administration of the agent, and/or allow the 
agent to be administered in greater amounts or for longer periods of time.  
 
 A good understanding of elimination (metabolism and excretion) of the agent 
is also necessary. Conversion of the agent to metabolites, known as 
biotransformation, occurs primarily via enzymatic reactions in the liver, although 
other tissues may also be involved, e.g., lungs, kidneys, or GI mucosa, etc.75 
Biotransformation can have several effects, including inactivation of the agent (the 
resulting metabolite(s) does not exert the intended effect), its activation (e.g. a pro-
drug, where the metabolite exerts the intended effect), modification of activity (the 
resulting metabolite(s) exerts a secondary effect), or toxicity (the resulting 
metabolite(s) interrupts a normal cellular metabolic pathway which results in cell 
death).76 Excretion from the body is also an important consideration. Excretion 
occurs primarily via the kidneys or also the liver, GI tract, and lungs, and this 
process lowers the concentration of agents in the body, which in turn can reduce 
both efficacy and toxicity.75 Other efforts in drug delivery also hold promise to 
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improve multiple pharmacokinetic parameters, for example, controlling the rate of 
release of agents at the target site to maximize the therapeutic outcome.77  
 
 As mentioned, addressing these problems in drug delivery is critical to 
improving many medical treatments. Neurological, cancer, cardiovascular, 
infectious, immune, and genetic disorders are only a few examples of the many 
applications where drug delivery science can have a major impact by addressing 
challenges imposed by the physiology of the body, e.g., solubility of agents in 
physiological fluids, adequate and selective accumulation at the target tissue versus 
non-target tissues, passage from the bloodstream to the tissue compartment, 
accumulation  in the appropriate cell type and subcellular compartment,  reducing 
premature degradation, etc. 
 
2.2. Drug Delivery Systems   
The use of drug delivery systems to enhance the pharmacokinetics and effects of 
pharmaceutical agents has increased through advancements in nanotechnology 
known as nanocarriers. Nanocarriers of a diverse range of sizes (a few nanometers 
up to one micrometer), geometry, materials, and surface chemistries are now being 
developed to meet particular medical needs (Figure A).78 For example, poorly 
soluble agents are being encapsulated in drug carriers to improve solubility in 
blood.78 Therapeutics that are susceptible to pH or enzymatic degradation,79 or 
which may be effluxed from cells by drug transport pumps,80 can be loaded into 
nanocarriers as a means to address these issues. In addition to these advantages, 
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nanocarriers are being developed to have high loading capacity, increased 
biocompatibility and  accumulation at the site of activity, enhanced functionality (i.e. 
adding surface coatings, targeting moieties, or therapeutic and imaging agents), and 
to enable controlled release of cargo.2,78,81-83  
 
 
Figure A. Some structures of nanocarrier drug delivery systems  
 
 Liposomes were first reported in 1965, making them the oldest type of 
nanocarrier delivery system.84 They are made by self-assembly of amphiphilic lipids 
in aqueous solution to form bilayered spherical vesicles with an aqueous lumen, and 
range in size from 50 nm to several microns.85 The material composition of 
liposomes includes phospholipids found naturally in cell membranes as well as other 
membrane constituents such as cholesterol.86 Due to  this liposomes are generally 
biologically inert, which results in low toxicity.87 In addition, they can be 
functionalized with targeting moieties and with polymer coatings (e.g. polyethylene 
glycol (PEG)) to provide selective targeting and/or imaging, and to limit clearance 
due to opsonization in the bloodstream.85 Because they are amphiphilic, hydrophilic 
agents can be loaded in the interior lumen or surface while hydrophobic agents may 
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be loaded in the bilayer.85 Liposomes also have some disadvantages, including a 
relatively low drug loading capacity, and the fact that the liposomal bilayer can 
become destabilized in the circulation by high density lipoproteins, resulting in 
premature release of cargo.88 However, incorporation of certain lipids (e.g. 
phosphatidylcholine, sphingomyelin) or cholesterol in the liposomal membrane can 
increase stability.87 Liposomes are also sensitive to destabilization by modification, 
e.g., can tolerate a relatively low number of targeting moieties before becoming 
destabilized.89  
 
 Polymeric nanocarriers are fabricated from synthetic, natural, or hybrid 
polymers which are defined as macromolecular entities created by covalent and 
repeated linkage of smaller structural units.82 The main criteria for selection of 
polymeric materials are biocompatibility and degradability (properties which are 
important for limiting toxicity), controlled release, and excretion from the body. 
Poly(ethylene glycol) (PEG), poly(methyl methacrylate) (PMMA), and  poly(lactide-
co-glycolide) (PLGA) are commonly used synthetic polymers, with PEG also being 
widely utilized as a surface coating to reduce clearance from the circulation87 and 
PLGA being FDA approved for use in drug delivery systems due to its 
biocompatibility.90,91 Natural polymers made from gums, polysaccharides, and 
polypeptides (e.g. chitosan, sodium alginate, gelatin, albumin, etc.) are also utilized, 
offer lower batch-to-batch variability, and are potentially less toxic since they do not 
require use of chemicals during fabrication.92-94 In addition to biocompatibility and 
degradability, polymeric materials are widely utilized because of their controllable 
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geometry. For example, polymeric nanocarriers can be fabricated in a wide variety 
of sizes (10 nm -1µm) and shapes (spheres, rods, disks, toroids, plugs, etc.)95 with a 
hollow lumen or solid cores, and controllable porosity.96 Functional agents 
(therapeutic, imaging, or targeting) can be added to the particle surface, core, or 
embedded throughout the polymer matrix.97 Importantly, polymeric carriers are 
more tolerant of functionalization than liposomes without compromising carrier 
stability.98 Controlled release can be achieved by diffusion, surface erosion, or bulk 
degradation of the nanoparticle over time.77 Linear and branched polymers as well as 
polymerosomes, dendrimers, polymeric micelles, and niosomes can also be 
fabricated from polymeric materials.  
 
 Polymerosomes are considered the polymer analog of liposomes, with the 
difference that they are made from amphiphilic block copolymers instead of 
phospholipids.99 Like liposomes, polymerosomes range in size from tens of 
nanometers to several microns, can be loaded with both hydrophilic and hydrophobic 
agents and are not very toxic, but in contrast are also more rigid and less permeable. 
This allows a greater number of functional moieties to be added and increases 
stability.  
 
 Dendrimers are named for their tree-like structure and are generated by 
adding layers of polymers sequentially around a central core either via convergent or 
divergent synthesis.100,101 The result is a highly branched polymer network where 
functional agents may be entrapped within the layers or coupled to the dendrimer 
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surface.102 The small size of dendrimers (only a few nanometers in diameter) is 
advantageous for oral delivery, allowing dendrimers to permeate through the 
epithelial cellular barrier of the GI tract.103 As with other types of polymeric 
materials, dendrimer physical properties such as size, shape, and surface chemistry 
are controllable, which  in this case is achieved by modifying the generation 
number.101 A high surface-to-volume ratio allows for addition of a high number of 
functional groups, e.g., therapeutic, diagnostic, and targeting moieties.101 
Disadvantages of dendrimers include costly manufacturing, difficulties with quality 
control due to multi-step synthesis, and potential for toxicity in vivo.74 
 
 Polymeric micelles are also made from amphiphilic block copolymers which 
self-assemble to form a hydrophilic shell and a hydrophobic core.104,105 Similar to 
dendrimers, polymer micelles are small in size (a few nanometers in diameter), yet 
in contrast have an inner hydrophobic core and an outer hydrophilic layer.104 As with 
other polymeric carriers, micelles can be functionalized for targeting, formulated 
with low toxicity materials, designed to have a relatively high loading capacity for 
water-insoluble drugs, controlled release, prolonged blood circulation, and also self-
assemble in aqueous solution resulting in simple formulation.104 
 
 Niosomes are vesicles formed using non-ionic surfactants, such as glycerol, 
glycerol esters, polysorbates, etc. Like liposomes, niosomes have both hydrophilic 
and hydrophobic domains, allowing for incorporation of agents with a range of 
solubilities. The niosome composition, fluidity, size, and lamellarity can be 
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controlled,106  allowing for versatile nanocarrier design. In addition, surfactants are 
generally biodegradable, biocompatible, non-immunogenic, and relatively non-toxic 
due to their lack of charge.106  
 
 Inorganic nanoparticles are also being explored for drug delivery, including 
carbon nanostructures, quantum dots, metal particles, and mesoporous silica 
nanoparticles, and are used mainly for diagnostic applications. Carbon 
nanostructures are fabricated into various forms such as nanotubes.107They are stable 
and the structural conformation, charge, strength, flexibility can be varied, and can 
be functionalized with drugs and/or biomolecules for diagnostic and therapeutic 
purposes.107Quantum dots (QDs) are semiconductors fabricated from a combination 
of metals and non-metals.108 These nanoparticles (~2-10 nm diameter) have greater 
fluorescence than traditional fluorophores, excitation and emission wavelengths can 
be tuned by the particle size, and are detected with a high level of sensitivity.109 
Metal nanoparticles such as iron oxide and gold are used as imaging agents due to 
their sensitive detection and stability.110 Iron oxide and superparamagnetic iron 
oxide (SPIO) metal nanoparticles show potential for magnetic resonance 
imaging111,112 and are also being exploited for targeting.113 Gold is a biocompatible 
material which can be modified with numerous biomolecular agents for diagnostic 
and therapeutic applications.114 Mesoporous silica nanoparticles are have been 
heavily investigated recently due to their controllable mesoporous structure (e.g. 
porosity diameter ~2-50 nm), high specific surface area, and large pore volume.115 
This has been advantageous for loading of therapeutic cargoes, including small 
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molecules, therapeutic proteins, and genes.115 Ceramic materials in general are 
highly stable and, like PLGA, silica is considered a “Generally Recognized As Safe 
(GRAS)” material, making it promising for clinical studies.115 These and many other 
nanocarrier-based drug delivery systems offer a means to optimize the 
pharmacokinetics of agents for particular medical needs. As mentioned above, most 
of these drug delivery systems can be functionalized to target sites of intervention in 
the body. In order to enhance delivery to the intended site, various targeting 
strategies may be utilized. 
 
2.3. Targeting Strategies in Drug Delivery 
In the broadest sense, to target a physiological system means to enable its interaction 
with a specific component of that system. Targeting occurs naturally as part of the 
normal physiological function of the body and also in pathophysiologal contexts. For 
example, at the subcellular level, components of the cell machinery such as 
microRNAs target specific genes in order to modulate their expression and, as a 
result, alter cell function, signaling, or sorting peptides of proteins for distribution to 
different compartments.116 At the cellular and tissue/organ levels, infectious 
pathogens such as viruses or bacteria and cells of the immune system can gain access 
to specific cells, tissues, and/or organs by targeting molecules present on the cell 
surface.117 Targeting also occurs at the level of organ systems, where ligands (e.g. 
metabolites, hormones, neurotransmitters, growth factors, etc.) travel from and to 
specific organs or tissues via the circulation.118 Therefore, targeting occurs naturally 
and at several levels of organization/complexity as part of normal physiological 




 Targeting for drug delivery was first theorized by Paul Ehrlich in the 1900’s, 
who envisioned coupling a therapeutic cargo to an element which enabled specific 
binding to the target site.1  Since then, targeting has been explored and expanded 
upon as a strategy to enhance delivery of agents to specific organs, tissues, cells, and 
more recently specific subcellular compartments.3 Yet, targeting is a challenge 
which is intrinsically complex.3 A targeted agent must first reach the target site at the 
organ level, whether via the systemic circulation or administration via other routes 
(e.g. inhalation/intratracheal installation for pulmonary delivery, 
intrathecal/intranasal/intracarotid for brain delivery, GI for oral delivery, etc.). 
Depending on the tissue of interest, the agent may have to traverse additional 
barriers to reach the tissue of interest (e.g.  the blood-brain barrier, the intestinal 
epithelial barrier, mucus barriers of the lung airways, GI tract, eyes, etc.).67,72 The 
agent must then reach the intended tissue and cell type via mass transport (e.g. 
diffusion, convection, etc.). If the site of activity is intracellular, the agent must 
further bind and enter the cell, traffic to the intended subcellular compartment, and 
interact with the molecular target.3 
 
 In current practice targeting strategies for drug delivery generally fall into 
four categories (Figure B). Passive targeting occurs when agents accumulate in 
certain locations of the body due to the physiological features and function of these 
sites.3 Examples of passive targeting include accumulation in spleen and liver due to 
opsonization and subsequent clearance from the circulation by the 
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reticuloendothelial system at the organ level (or the monocyte-macrophage system at 
the cellular level),18 or in sites afflicted by tumors where “leakiness” of the 
vasculature caused by the tumor microenvironment gives rise to the enhanced 
permeability and retention effect.68 The converse of passive targeting is inverse 
targeting, where the goal is to block passive accumulation of the administered agent 
in order to enhance targeting to other sites.3  For example, administration of empty 
liposomes prior to administration of adenoviral vectors enhanced gene transfer to 
hepatocytes by transiently saturating uptake via hepatic kupferr cells.119 In contrast 
to passive or inverse targeting, active targeting involves adding targeting properties 
on the agent either intrinsically or extrinsically. Intrinsic active targeting refers to 
selecting or modifying the therapeutic agent itself to improve targeting specificity.120  
On the other hand, extrinsic active targeting involves coupling the agent to a 
component which possesses targeting features. This can be accomplished by 
physical means (e.g. pH,121 temperature,122,123 etc.) where the agent is coupled to a 
component which enables activation or release at the target site due to features of the 
target environment or via an external stimulus.122 In addition, the modifying 
component can be a ligand which displays affinity for particular determinants (e.g. 
cell-surface molecules) present at the site of disease.3 The targeting ligand can be 
coupled directly to the agent or to the surface of a nanocarrier delivery system.3 
Finally combined targeting refers to using a combination of the other targeting 
approaches.3 For example, carriers can been designed using a pH-sensitive 
polymeric material and also a targeting ligand to enable targeting via both intrinsic 
and extrinsic active-targeting for cancer therapy.124 
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Figure B. Drug targeting strategies.  
 
2.4. Targeting to Cells and Subcellular Compartments 
Active targeting with ligands is a heavily investigated form of targeting which has 
been utilized to improve specificity of nanomedicines under development.3 This 
targeting allows agents to associate to, for instance, cells of interest, resulting in 
increased specificity for the target site. This association can be either “promiscuous” 
or selective depending on the strategy which is utilized. In the case of non-selective 
targeting, an agent is functionalized with a polycationic or amphipathic targeting 
peptide (e.g. Tat, octa-arginine, Penetratin, etc.) that enables adhesion to cells in a 
broad manner.125-128 These peptides are termed cell-penetrating peptides because 
they also enable transport into cells.128 A promiscuous targeting strategy is 
advantageous for treatment of diseases affecting multiple organs (e.g. the lysosomal 
storage disorders and other monogenic diseases, oxidative stress, etc.),96 in cases 
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where accumulation of the agent in off-target sites will not produce significant side 
effects, or for prophylactic applications.3 However, for many applications non-
selective targeting is considered a disadvantage, such as delivery of cytotoxic agents 
in cancer therapy.  
 
 In contrast to non-selective targeting, specific targeting enables association to 
cells by binding specific molecules (e.g. receptors, enzymes, mucins, etc.) present on 
the surface of cells.3 Binding is an equilibrium between the ligand and the target, and 
therefore is affected by both the target and ligand concentrations as well as the 
accessibility of both of these components. Expression of the target is, therefore, an 
important factor which can be modulated by cell activation (e.g. increased 
expression of certain adhesion molecules28 is observed in response to inflammatory 
stimuli, while expression of other molecules is decreased due to cleavage by 
proteases).3 On the other hand, the concentration of available ligands can be adjusted 
according to the administered dose, by adjusting the number of ligands coupled 
directly to the agent or indirectly to a nanocarrier delivery system.129,130 
 
 In terms of accessibility, the target must be displayed on the cell surface 
rather than intracellularly. Yet, access to the target molecule may be hindered if the 
molecule is part of a complex or interacts with other molecules on the cell surface.3 
The precise location of the target epitope is also critical. For example, targeted 
agents may compete with endogenous ligands for binding at certain receptor 
epitopes. Also, binding certain domains of a receptor can modulate its own 
 
22  
expression. For example, binding of angiotensin converting enzyme (ACE) at certain 
epitopes induces shedding from the plasma membrane.131 Masking of the binding 
epitope may occur in certain cell types or tissues due to post-translational 
modifications, or it may be less accessible or eliminated in certain receptor 
isoforms.3 Epitope dependent targeting is also observed with regard to in vivo 
biodistribution, where targeting different epitopes of the transferrin receptor (TfR) 
affects selectivity for the brain versus other organs.132 Finally, if the target site is 
intra- or transcellular, an epitope that triggers transport into the cell via membrane-
bound vesicles (endocytosis) into or across the cell must be selected.3  
 
 Importantly, therapeutic targets are present on the plasma membrane or in 
intracellular compartments and, therefore, targeting strategies enabling delivery at 
the subcellular level is necessary.2 Anchoring therapeutics to the plasma membrane 
can be utilized, as an example, for prophylaxis of thrombosis or inflammation, and 
can be accomplished by targeting cell-surface molecules which are poorly 
internalized (e.g. antibodies targeting intercellular adhesion molecule 1 (ICAM-1)).28 
Lysosomal targeting is essential for many enzyme replacement therapies of 
lysosomal diseases, and can be achieved by targeting many different cell-surface 
molecules including ICAM-1,133,134 mannose-6-phosphate receptor,135 insulin growth 
factor II,136 the low density lipoprotein receptor family,137 insulin receptor, 
transferrin receptor,138,139 and many others.3 Mitochondrial dysfunction is associated 
with many diseases including cancer, diabetes, as well as cardiovascular and 
neurological conditions.140 Delivery to the mitochondria can be achieved by using 
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targeting peptides containing mitochondrial localization sequences,141,142 cytochrome 
oxidase subunits,143 or retinoic-inteferon-induced mortality proteins.143  Nuclear 
delivery is needed for gene therapy and for therapeutics with nuclear targets (e.g. 
cytotoxic agents), and may be accomplished using nuclear localization sequences 
which target import proteins present on the nuclear envelope.144 Targeting is 
necessary for most agents intended for the nucleus as  the size cutoff for passive 
diffusion across nuclear envelope pores is 30-40kDa. Targeting the Golgi apparatus 
and endoplasmic reticulum is less well defined, yet has been utilized for certain 
cytotoxic cancer agents via conjugation to shiga or cholera toxins which target these 
organelles by binding to molecules on the cell surface and subsequent endocytic 
transport.145 
 
2.5. Transport Into or Across Cells  
Transport from the surface to the interior of cells can occur either directly from the 
extracellular space to the cytosol or by vesicular uptake resulting from endocytosis.3 
Direct transport can occur via passive diffusion, although this is restricted to small, 
hydrophobic molecules such as small alkanes, benzene, diethyl urea, etc.146 Active 
direct transport can occur for ions and various small molecules to move against their 
concentration gradients as substrates of transporter pumps.147,148 Approaches 
involving disruption of the plasma membrane with a transiently applied physical 
stimulus (e.g. electroporation, ultrasound, hydroporation, magnetofection, ballistic) 
have also been utilized to enable transport into the cytosol.149-154 However these 
approaches are damaging and are only used locally. Positively-charged cell 
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penetrating peptides or toxins can also provide direct transport to the cytosol by 
transiently forming pores in the plasma membrane.155-157 In contrast, agents targeted 
to surface molecules can be transported intracellularly by endocytosis.3 Endocytosis 
is preferable for nanocarriers because their size restricts passive diffusion across the 
plasma membrane or transport via transporter pumps.  
Figure C. Mechanisms of endocytosis.  
  
 Several different mechanisms of endocytosis have been elucidated, and 
multiple are involved in uptake and intracellular transport of nanocarriers (Figure C). 
Phagocytosis involves the uptake of relatively large (up to several micrometers in 
size) amounts of extracellular particulate matter into the cell.20 Phagocytosis can be 
induced by cross-linking of certain cell receptors and results in uptake into a 
vesicular compartment termed the phagosome, with subsequent transport to 
lysosomes which function as a degradative compartment in the cell.158 Targeting of 
the mannose receptor or of integrins CD11b/CD18, binding of the Fc class of 
receptors via the constant region of antibodies, or targeting of other receptors can 
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enable uptake into cells by phagocytosis.158 The ability to take in large material 
represents an advantage from the standpoint of drug delivery, because nanocarrier 
size may be used to control the rate of clearance from the circulation, amount of drug 
loading, etc. In addition, phagocytosis can be controlled by nanocarrier shape, where 
a high degree of surface curvature at the ends of rod-like structures increase 
induction of phagocytosis relative to more spherical structures.159 On the other hand, 
although lysosomal delivery is needed in certain contexts (e.g. therapy of lysosomal 
storage disease), it represents a relative disadvantage in most contexts.3 In addition, 
phagocytosis occurs primarily on cells which are professional phagocytes (e.g. 
macrophages), limiting targeting to cells of the reticuloendothelial system (RES).20 
Although this may be advantageous in certain cases, RES-mediated clearance is 
largely undesired in most contexts, as it hinders delivery to other areas of the body.  
 
 In contrast to phagocytosis, macropinocytosis involves uptake of 
extracellular fluid (e.g. pinocytosis) into cells (Figure C). Macropinocytosis is 
induced by binding of growth factors which stimulate receptor tyrosine kinases and 
subsequent intracellular signaling produces ruffling of the plasma membrane and 
reorganization of the actin cytoskeleton to accommodate engulfment of fluid and 
nutrients from the extracellular milieu.160 Since vesicles of 0.5µm to 5µm form as a 
result, this pathway can also potentially take up carriers of large sizes and it’s 
involvement in uptake of various nanocarriers has been demonstrated.161 On the 
other hand, the uptake of nanocarriers via macropinocytosis is more difficult to 
control for drug delivery purposes, as it is often non-specific, and the intracellular 
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fate is variable but often involves acidification and shrinkage of the compartment, 
eventual delivery to lysosomes, or recycling to the cell surface.162 
 
 Clathrin-mediated endocytosis is perhaps the best characterized mechanism 
of endocytic transport and is also pinocytic (Figure C). It can be accessed with or 
without ligands targeted to molecules such as transferrin receptor (TfR), vascular 
cell adhesion molecule 1 (VCAM-1), αvβ3 integrin, LDL receptor, selectins, and 
many others.3 Binding of the target receptors on the cell surface induces uptake by 
forming invaginations on the plasma membrane with the aid of a clathrin coat, and 
endocytosed material is delivered initially to endosomes with subsequent recycling 
to the cell surface, delivery to lysosomes, or transcytosis.20,163 Clathrin-mediated 
endocytosis is ubiquitous to most cells which can be useful in applications where 
endocytic transport in multiple cell types may be necessary (e.g. sequential transport 
across the blood-brain barrier, followed by endocytosis in parenchymal cells).164 
However, a disadvantage is that the size of internalizable ligands via clathrin-
mediated endocytosis is limited to ~100-150 nm, restricting internalization to 
monovalent drug conjugates and carriers below this size.162  
 
 Caveolae-mediated endocytosis is pinocytic and can be accessed with or 
without the use of targeting ligands. Endocytosis via caveolae can be triggered as 
result of binding to molecules such as aminopeptidase N and P, gp60, and others.3 
Caveolae are distinctive, flask-shaped invaginations on the plasma membrane and 
are prevalent in endothelial cells.165,166 Endocytosis via caveolae presents an 
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advantage primarily because it results in transport to a sorting compartment known 
as the caveosome with subsequent transcytosis to the basolateral surface.167 This 
along with the observation that transcytosis is more common to caveolae- than 
clathrin-mediated endocytosis,3 make this pathway advantageous for crossing 
cellular barriers. Similar to clathrin-mediated endocytosis, however,  the size of 
internalizable ligands is restricted by lack of accessibility of target receptors due to 
their location deep within caveolar invaginations, or because the size of caveolar 
vesicles is limited to ~70 nanometers.3  
 
 Non-classical pathways such as flotillin-, cdc42-, RhoA, and Arf6-dependent 
pathways can also be utilized.161 These pathways are involved in transport of cargoes 
such as simian virus 40, cholera toxin, glycosylphosphatidylinositol (GPI)-linked 
proteins, interleukin-2, and growth hormones.161 Nanomaterials utilizing these 
mechanisms have been documented in rare cases, such as macromolecules modified 
to target folate.161 
 
  In certain cases, endocytic pathways which have not been described to be 
constitutive can be induced by binding of receptors even when these are not 
commonly associated with endocytic transport. This is the case for intercellular 
adhesion molecule-1 (ICAM-1) or platelet-endothelial cell adhesion molecule-1 
(PECAM-1), where binding of targeted nanocarriers or conjugates to multiple copies 
of the receptor induces endocytosis via an uncommon pathway termed cell adhesion 
molecule-mediated endocytosis (CAM)-mediated endocytosis.168 Polymer 
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nanocarriers targeted ICAM-1 or PECAM-1 have been observed to use this 
mechanism of endocytic transport.168-173 The advantages of CAM-mediated 
endocytosis include presence in several cell types, including endothelial, epithelial, 
macrophages, fibroblasts, neurons, etc.3 Endocytosis via the CAM pathway can 
accommodate uptake of carriers up to 5 microns in size and, enables slow transport 
to lysosomes, which can be exploited to prolong activity of therapeutics before 
degradation,169 or enables transcytosis.19 The disadvantages of CAM-mediated 
endocytosis include relatively little knowledge of the precise mechanics of endocytic 
transport and fate in subcellular compartments, and also that targeting ICAM-1 or 
PECAM-1 may result in broad distribution in tissues which is unwanted for certain 
applications (e.g. delivery of cytotoxic agents). 
 
 As mentioned above, several endocytic pathways allow transcytosis which 
enables vesicular transport across cell barriers (e.g. the blood-brain barrier) to reach 
target sites in the tissue parenchyma.174 Transcytosis can occur as a result of uptake 
via the fluid phase, or can be receptor-mediated where the target molecule is bound 
at the apical cell surface, endocytosed, and transported across the cell to the 
basolateral cell surface via vesicular trafficking.174 An advantage of transcytosis is 
that it can allow transport without disrupting cell junctions. Opening of cell junctions 
can induce toxicity due to concomitant transport of substances in the extracellular 
milieu. Certain molecules associated with clathrin-mediated endocytosis, such as 
TfR, LDLR, and insulin receptor are known to enable transcytosis,3,174 but 
transcytosis via caveolae also occurs via ligand binding and is more common.3 As 
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with intracellular delivery, a significant drawback of these routes is that uptake is 
restricted by size which limits the potential transport of nanocarriers. Transcytosis 
via CAM-mediated endocytosis may provide a preferable alternative as intracellular 
uptake of relatively larger carriers is accomodated.175  
 
 Transport via paracellular routes (i.e. between cells)  is also possible, but 
requires disruption of tight junctions linking adjacent cells (Figure D). This can be 
done transiently with certain nanocarriers (e.g. dendrimers) or by using 
hyperosmotic solutions, vasoactive agents, ultrasound, solvents, or stabilizers.5 
However, these strategies are transient and local, and can be invasive or damaging 
due to toxic effects associated with induction of barrier permeability. Finally, 
carrier-mediated transport and passive diffusion are other potential routes of 
transport across cells, but are limited to small molecules.  
 
 




2.6. Targeting and Endocytosis of Nanocarriers: Role of Size and Valency 
With regard to targeting and transport of agents, the targeting valency (number of 
ligands utilized) and size of nanocarriers have an impact on most aspects of 
pharmacokinetics. One clear advantage of targeted nanocarriers over simple 
conjugation of an agent to an affinity moiety is that the design is amenable to 
modifications which add functionality or improve the pharmacokinetic profile (e.g. 
nanocarriers shape, structure, surface coatings, etc). Multivalent display of targeting 
ligands on the nanocarrier surface can also affect drug delivery on several levels. For 
example, multivalency can accelerate clearance from the circulation by increasing 
recognition by cells of the reticuloendothelial system.176 This is very apparent in the 
case where antibodies, recognizable by their Fc region, are used as targeting 
ligands.176 Avidity for the target receptor is enhanced by ligand multivalency which 
can, in turn, enhance binding.3 This is particularly important in vivo, where 
physiological factors such as shear stress from the flow of blood, or competition for 
the target epitope with endogenous ligands can work against effective targeting.3  
Yet, multivalency may also enhance binding to off-target sites, which, despite lower 
expression of the target, may be amplified by higher avidity for the target receptor 
than monovalent drug conjugates.3 Regarding internalization, binding multiple target 
molecules on the cell surface may enhance nanocarrier internalization. For example, 
in the case of ICAM-1 targeting, only multivalent binding with ICAM-1-targeted-
nanocarriers, but not free anti-ICAM, enables endocytosis.168 Multivalency can also 
affect subcellular transport as has been observed for the slow trafficking to 
lysosomes of multivalent transferrin oligomers versus monomeric transferrin.177 
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Multivalency may also enhance adhesion to components of the extracellular matrix 
within tissues, but this has not been examined. Therefore, the behavior of a targeting 
moiety when coupled to a nanocarrier may be completely different from  that 
observed from the naked targeting moiety. 
 
 The size of the nanocarrier also affects delivery on many levels. Size is 
inversely correlated with the rate of clearance from the circulation, due to increased 
adsorption of opsonins and subsequent recognition by macrophages in the spleen and 
liver.18 Steric hindrance can lower the ability of nanocarriers to bind the target 
receptor which may also depend on the expression level and location of the the target 
receptor on the plasma membrane.3,129,178 This is particularly apparent when the 
target epitope is proximal to the plasma membrane, affecting binding of nanocarriers 
to the target receptor.179 Intracellular transport of targeted nanocarriers also seems to 
be affected by size, e.g. in the case of targeting to ICAM-1, micron-sized spheres 
reach the lysosomes at a slower rate than submicron-sized counterparts.175 In 
addition, size may restrict internalization via certain pathways altogether.180 Larger 
size also lowers the ability of nanocarriers to diffuse to the target site, yet lymphatic 
drainage may also be lower.3 Therefore, nanocarrier size effects may be offset by 
comparatively greater retention in tissues than smaller drug conjugates.  
 
 Overall, size and valency have advantages and disadvantages which cannot 
be predicted a priori, and therefore must be evaluated empirically according to the 
particular target, cell type, carrier, pathological status, and therapeutic intervention.3  
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2.7. Combination Targeting 
Apart from valency and size described above, targeting can also be modulated by 
combination targeting of nanocarriers. Combination targeting is an emerging 
approach for drug delivery to enhance or improve control over the distribution of 
nanomaterials in the body. It is seen in nature with infectious pathogens and cells of 
the immune system which interact with multiple cell-surface receptors to adhere to 
and induce transport into cells or across cellular barriers.10,21 Combination targeting 
strategies have also arisen in targeted drug delivery, providing new approaches to 
enhance and optimize delivery of therapeutics and imaging agents for a number of 
applications.  
 
 One of the most studied examples of combination-targeting is that of 
targeting multiple CAMs expressed on the vascular endothelium.12,23,30,181-187 
Endothelial CAMs consist of selectins (E- or P- selectin) and immunoglobulin-like 
CAMs (ICAM-1, PECAM-1, and vascular cell adhesion molecule-1, VCAM-1) 
which are involved in the adhesion and transmigration of leukocytes to sites of 
inflammation.21 Selectins mediate the initial tethering and rolling interactions of 
leukocytes on the endothelial surface by forming relatively weak, catch-slip bond 
interactions, while Ig-like CAMs mediate firm adhesion and transmigration of 
leukocytes across the endothelial border by engaging in stronger binding 
interactions.21 An important application of targeting CAMs is delivery of 
pharmaceutical agents to the vascular endothelium which is involved in the 
pathogenesis of many diseases.188 Nanocarriers have been targeted to particular 
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CAMs in order to enhance delivery of imaging and therapeutic agents in many 
contexts, including treatment of inflammation, cancer, atherosclerosis, arthritis, 
thrombosis, and lysosomal storage disorders.21 CAMs provide endocytosis into 
endothelial cells via clathrin-mediated (E- or P- selectin, VCAM-1)189-192 or CAM-
mediated (ICAM-1 and PECAM-1)168 endocytosis, respectively. The endothelium is 
also a critical barrier restricting transport from the circulation to the organ 
parenchyma. ICAM-1 and VCAM-1 have been shown to enable transport of 
nanocarriers across endothelial or epithelial cells via transcytosis which may provide 
a useful means to deliver nanocarrier cargo from the bloodstream to extravascular 
tissues.19,193 
 
 Although a relatively nascent strategy, combination targeting of CAMs has 
been explored in several contexts. For example, microparticles carrying iron oxide12 
or fluorescent probes,182 perfluorocarbon-filled microbubbles,23,30 or gold 
nanorods187 have been used in imaging, and polymerosomes,186 
immunoliposomes,184,185 or PLGA microspheres181 have been developed for  drug 
delivery applications. These examples emulate adhesive properties of leukocytes by 
combining targeting to an endothelial selectin and an Ig-like CAM.12,23,30,181-187 
Simultaneous targeting to these molecules is beneficial, as demonstrated for 
microspheres functionalized with sialyl Lewis(X) and anti-ICAM, for which certain 
ligand-receptor ratios and flow shear rates allowed binding only through interaction 
with both receptors, enhancing selectivity.181 Targeting polymerosomes to P-selectin 
and ICAM-1 also enhanced binding over single-targeted counterparts and improved 
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selectivity toward inflammation,186 and combined P-selectin/VCAM-1 targeting 
seemed to improve binding of microbubbles in receptor-coated flow chambers.23 
These “leukomimetic” approaches are being explored for treatment and/or diagnosis 
of inflammation, atherosclerosis, and cancer. Combination-targeting to molecules 
with different function has also been examined in particular contexts, and has been 
shown to enhance transport to tumor areas,13,194,195 improve site selectivity,14 and 
enhance delivery to multiple cell types within the tumor environment.7   
 
 On the other hand, targeting nanocarriers to multiple epitopes of the same 
receptor is completely unexplored.  Epitope dependent targeting has been observed 
for nanocarriers targeted to single receptors. Binding, endocytosis, and lysosomal 
transport of PECAM-1-targeted nanocarriers were shown to depend on the epitope 
targeted.179 Epitope selection is important for lung accumulation and induced 
cleavage of anti-ACE,131,196 and brain selectivity of anti-TfR.132 In addition, 
stimulation in vivo of PECAM-1 with an antibody subsequently enhanced lung 
accumulation of a second antibody or fusion conjugate.15  
 
 Interestingly, newer generations of nanocarriers are being developed to have 
spatially-segregated display of ligands on the nanocarrier surface.197,198 These 
“patchy” or janus nanoparticles may enable more precise control of ligand-receptor 
interactions  which could be utilized to optimize combination targeting strategies in a 
more rational manner. For example, ligands could be diplayed at varying distances 
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from one another, or in different patterns on the nanocarrier surface to develop 
control over targeting. 
  
 Translation of these strategies requires a good understanding of their impact 
on cellular binding, internalization and biodistribution in vivo. Yet, much remains to 
be done with regard to these areas. Targeting nanocarriers to multiple epitopes of the 
same receptor has never been examined in these contexts, and only a few examples 
have been published in the case of targeting receptors with similar or different 
function. Consequently, the behavior of nanocarriers with regard to these parameters 
and targeting strategies remains largely an open question.   
 
 The results presented in this dissertation provide insight into the performance 
of model polymer nanocarriers designed for combination targeting. Nanocarriers 
targeted to multiple receptors with similar function is investigated in the context of 
multi-CAM-targeting (Section 4.1). Nanocarriers are targeted to multiple Ig-like 
CAMs in single, dual- or triple-targeted combinations, and binding, internalization 
within cells, and biodistribution in vivo are evaluated. Combination targeting of 
polymer nanocarriers to different receptors is investigated next (Section 4.2) using 
ICAM-1 and TfR which are involved in leukocyte adhesion vs. iron transport. 
Finally, a novel approach for combination targeting is presented (Section 4.3) where 





Section 3: Methods 
3.1. Materials  
Monoclonal antibodies used in the study were: mouse anti-human TfR clone T56/14 
from  EMD Millipore (Billerica, MA), rat anti-mouse TfR clone R17217 (hereafter 
referred to as R17) from Biolegend (San Diego, CA),132 rat anti-mouse TfR clone 
8D3 from Novus Biologicals (Littleton, CO),199 mouse anti-human ICAM-1 clone 
R6.5200 and rat anti-mouse ICAM-1 clone YN1 from ATCC (Manassas, VA),201 rat 
anti-mouse PECAM-1 clone MEC13 (BD Biosciences; San Jose, CA), and rat anti-
mouse VCAM-1 clone MK2 (Santa Cruz Biotechnology; Dallas, TX). ICAM-1-
targeting peptide, γ3 (NNQKIVNIKEKVAQIEA 37,202), was synthesized by United 
Biochemical Research (Seattle, WA). Transferrin (Tf) and secondary antibodies 
were from Molecular Probes (Eugene, OR). Recombinant human acid 
sphingomyelinase (ASM) was produced by our collaborator Dr. Schuchman (Mt. 
Sinai Hospital, NY) in chinese hamster ovary cells and purified as described.203 
Control rat and mouse IgG were from Jackson Immunoresearch (Pike West Grove, 
PA). Polystyrene particles were from Polysciences (Warrington, PA). Unless 
otherwise stated, all other reagents were from Sigma aldrich (St. Louis, MO). 
 
3.2. Iodination of Proteins 
Antibodies used to determine coating efficiency of antibodies on carriers or for in 
vivo studies in mice were labeled with 125I by adding ~20 µCi of 125I to 1 µg/µl of 
antibody and 2-3 iodination beads from Fisher Scientific (Waltham, MA) in a total 
volume of 100 µl of PBS for 3-5 min at room temperature. Iodogen pre-coated tubes 
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from Fischer Scientific (Waltham, MA) were also used in lieu of iodination beads 
for this procedure. Unincorporated 125I was removed by centrifugation at 1000g for 4 
min in a gel size exclusion column with 6,000 MW cutoff from Biorad (Hercules, 
CA). This column was prepared by inverting 2-3 times to homogenize the gel 
suspension, adding 2 ml of PBS to pack the column, and centrifuging at 1000g for 1 
min to remove PBS prior to adding the iodinated antibody. The concentration and 
activity of iodinated protein were determined by Bradford assay and measurement in 
a gamma counter, respectively. The percentage of free iodine remaining in solution 
was estimated by adding the 125I-antibody to 3% BSA and trichloroacetic acid (1 part 
in 6 v/v) which drives precipitation of the 125I-antibody but leaves free 125I in the 
supernatant fraction. Measurement of the activity of the supernatant relative to the 
total activity of the sample was used to determine the percentage of free iodine in 
solution. 
  
3.3. Preparation and Characterization of Antibody-coated Nanocarriers 
Model targeted polymer nanocarriers were prepared by coating ligands (Tf or γ3 
peptide) or antibodies onto the nanoparticle surface by adsorption. This results in a 
surface coating of antibodies which are randomly oriented on the nanocarrier 
surface, yet for all formulations tested this method resulted in specific binding 
relative to a control formulaton coated with non-specific IgG. As in our previous 
studies,134,175,204 and in order to avoid potential confounding results of concomitant 
nanoparticle degradation, we used model polystyrene nanoparticles which, after 
targeting with antibodies, have shown similar biodistribution than biodegradable 
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poly(lactic-co-glycolic acid) counterparts.205  This was done by incubating 0.7 mg 
antibody/mL with 9 x 1012 nanoparticles/mL for 1 h at room temperature, as 
described.206 Single-targeted nanocarriers contained only targeting moiety on the 
coat, i.e. control IgG (mouse or rat), Tf or anti-TfR (R17, 8D3, or T56/14), γ3 or 
anti-ICAM (YN1 or R6.5), anti-PECAM-MEC13, anti-VCAM-MK2, or a 1:1 mass 
ratio of control IgG and one of the targeting antibodies with valency of ~185-300 
antibodies per nanocarrier. Dual-targeted nanocarriers were coated by adding a 1:1 
mass ratio of anti-ICAM-YN1/TfR-R17, anti-TfR-R17/anti-TfR-8D3, anti-PECAM-
MEC13/anti-VCAM-MK2, or anti-ICAM-YN1/anti-PECAM-MEC13 which 
resulted in each antibody having a valency of ~99-154 antibodies per nanocarrier for 
a total of ~221-290 antibodies per nanocarrier. Triple-targeted nanocarriers were 
coated by adding a 1:1:1 mass ratio of anti-ICAM-YN1/PECAM-MEC13/VCAM-
MK2 with each antibody having a valency of ~67-92 antibodies per nanocarrier for a 
total of ~236 antibodies per nanocarrier. Nanocarriers carrying a therapeutic enzyme 
contained a 1:1 mass ratio of ASM and total antibody component (single, dual, or 
triple) mix. For experiments in mice, nanocarriers contained 125I-IgG or 125I-ASM as 
tracers the enzymatic cargo. Uncoated counterparts were removed by centrifugation 
at 13,800 g for 3 min. Nanocarriers were then resuspended to a final concentration of 
~6.8 x 1011 nanocarriers/mL (cell cultures) or ~5.8x1012 nanocarriers/mL (mouse 
studies) in phosphate-buffered saline (PBS) containing 1% bovine serum albumin 
(BSA) (cell cultures) or 0.3% BSA (mouse studies). These solutions were sonicated 
with 15-30 short pulses (i.e < 1 second/pulse) using a probe sonicator to avoid 
aggregation. The final size, polydispersity, and zeta potential of nanocarrier 
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formulations were estimated by dynamic light scattering or laser doppler velocimetry 
of electrophoretic mobility, respectively (Malvern Zetasizer, Worcestershire, UK). 
The coating density was assessed by preparing nanocarriers with 125I-labeled 
antibody and measuring the 125I content of the coated nanocarrier suspension in a 
gamma counter (PerkinElmer Wizard2, Waltham, MA). For dual or triple targeted 
formulations, only one of the antibodies was labeled per preparation to detect the 
valency of each antibody individually. The number of antibodies per nanocarrier 
were calculated as follows:  
 
Where NC = nanocarriers and CPM = counts per minute. 
 
3.4. Cell Culture 
Pooled human umbilical vein endothelial cells (HUVECs) from Lonza 
(Walkersville, MD) were seeded onto gelatin-coated coverslips and cultured at 37°C, 
5% CO2, and 95% relative humidity. Cells (3-4 passages) were grown in M-199 
medium supplemented with 15% fetal bovine serum (FBS), 2 mM glutamine, 
15 µg/ml endothelial cell growth supplement, 100 µg/ml heparin, 100 µ/ml 
penicillin, and 100 µg/ml streptomycin. Murine heart ECs (H5V)207 were seeded 
onto gelatin-coated coverslips at 37°C, 5% CO2, and 95% relative humidity in 
DMEM medium supplemented with 10% FBS, 2 mM glutamine, 100 µg/ml 
penicillin, and 100 µg/ml streptomycin. When indicated, pathological activation of 
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ECs was mimicked by 16-20 h incubation at 37oC with 10 ng/ml tumor necrosis 
factor alpha (TNFα). 
 
3.5. Binding Studies  
Cells were washed with basal cell medium (pre-warmed to 37oC, all washing steps 
involved 3 washes and 1 mL volume) before the nanocarrier incubation period to 
remove cellular debris. Control or TNFα-activated ECs were incubated with naked 
antibodies (~16.7 µg/ml) or antibody-coated carriers (~5 µg antibody/ml and 6.8 x 
1010 particles/ml) in cell medium at 37oC. The particular incubation times are 
specified in each figure legend. Following this incubation, cells were washed three 
times with 1 mL basal cell medium to remove unbound nanocarriers and fixed with 
cold 2% paraformaldehyde (PFA) for 15 min at room temperature. Where indicated, 
cells were fixed prior to incubation at room temperature with naked antibodies or 
antibody-coated nanocarriers, in order to examine binding in the absence of cellular 
activity (and consequently endocytosis).   
 
 Binding of naked antibodies on cells was detected by immunostaining with 
FITC-labeled secondary antibodies (goat anti-mouse or goat anti-rat IgGs). To detect 
antibodies both bound to the cell surface and internalized, cells were first washed to 
remove excess PFA, permeabilized with 0.2% Triton X-100 for 15 min at room 
temperature, washed, and subsequently stained with FITC-labeled goat anti-rat IgG. 
No additional staining was required to detect antibody-coated carriers since FITC is 
contained within the polymer matrix. Cell nuclei were stained with 4',6-diamidino-2-
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phenylindole (DAPI) for 5 min at room temperature prior to mounting onto slides 
with MOWIOL. 
 
 Fluorescence microscopy images were taken using an Olympus IX81 
microscope (Olympus, Inc., Center Valley, PA), ORCA-ER camera (Hamamatsu, 
Bridgewater, New Jersey), 60x objective (Olympus Uplan Apo F LN; Olympus) and 
FITC-optimized filter from Semrock (Rochester, NY, excitation BP460-490 nm, 
dichroic DM505 nm, emission BA515-550 nm). Images were acquired with 
SlideBook 4.2 (Intelligent Imaging Innovations, Denver, Colorado) and analyzed 
using Image-Pro 6.3 (Media Cybernetics, Inc., Bethesda, MD) to estimate antibody 
binding (mean fluorescence intensity),208 carriers bound per cell168 (number of 100–
200 nm fluorescent objects), or specificity index (e.g. targeting of antibody over 
control IgG or targeting of antibody-coated carriers over control IgG-coated 
carriers). Phase-contrast images were used to delimit the cell borders. 
 
3.6. Imaging of Endothelial Engulfment Structures  
To examine initial stages of carrier engulfment, HUVECs were incubated for 15 min 
at 37oC with anti-ICAM carriers or anti-TfR carriers, where carrier particles were 4.5 
µm to allow detailed visualization of engulfment structures.173 After washing 
unbound carriers, cells were fixed, permeabilized with 0.2% Triton X-100, and 
immunolabeled to detect enrichment of sodium proton exchanger 1 (NHE1) or 
clathrin heavy chain (which are partners associated to CAM vs. clathrin pathways)173 




3.7. Endocytosis Studies  
Control or TNFα-activated ECs were incubated with antibodies (~16.7 µg/ml) or 
antibody-coated carriers (~5 µg antibody/ml and 6.8 x 1010 particles/ml) ub cell 
medium as specified above. Iincubation times and temperatures are specified in 
figure legends. Cellular internalization was tested at 37oC, which is physiological 
temperature for eukaryotic cells. Following the incubation period, cells were fixed 
with PFA for 15 min at room temperature.  
 
 To detect targeting antibodies on the cell surface, cells were stained for 30 
min at room temperature with 6 µg/ml Texas-Red-labeled goat anti-mouse or goat 
anti-rat IgGs (which can bind to the Fc region of the targeting antibody), in PBS 
containing 1% BSA to block non-specific binding. Cells were then permeabilized 
with 0.2% Triton X-100 for 15 min at room temperature and subsequently incubated 
with 15 µg/ml FITC-labeled goat anti-mouse or goat anti-rat IgGs in 1% BSA PBS 
for 30 min at room temperature to stain both surface + internalized targeting 
antibody. In the case of antibody-coated nanocarriers, cells were stained with Texas-
Red-labeled goat anti-rat or goat anti-mouse IgGs to label nanocarriers present on 
the cell surface,168 while all cell associated nanocarriers (surface + internalized) had 
intrinsic green signal due to FITC-fluorophore embedded within the polymer matrix. 
Cell nuclei were stained with DAPI for 5 min at room temperature prior to mounting 




 Fluorescent microscopy was used to distinguish internalized materials as 
FITC single-labeled antibodies or carriers from surface-bound materials appearing 
yellow due to Texas-Red + FITC double-labeling. Images from each fluorescence 
channel were acquired (Texas-Red filter from Semrock (Rochester, NY), excitation 
BP360-370 nm, dichroic DM570 nm, emission BA590-800+ nm), merged, and 
analyzed using Image-Pro 6.3 to estimate the percentage of nanocarriers internalized 
per cell (% internalization) and the total number of nanocarriers internalized per 
cell.168 Percent internalization was calculated as the number of internalized materials 
divided by the signal for total cell-associated counterparts. Phase-contrast images 
were used to delimit cell borders.  
 
3.8. Biodistribution Studies in Mice 
Anesthetized C57BL/6J male mice (aged ~2-5 months and weighing ~20 – 30 g) 
were injected intravenously (28 G) via the jugular vein with 125I-labeled 
antibodies or antibody-coated nanocarrier counterparts (~1.3 mg total antibody/kg 
body weight, ~1.8 x 1013 particles/kg). Antibodies were directly labeled with 125I, 
while trace amounts of 125I-IgG (i.e. 0.03-0.24 µCI, ≤ 5% of total antibody) were 
used on the particle coat to enable detection in a gamma counter. This is particular 
useful for monitoring particle targeting upon administration because the distribution 
of non-specific IgG is clearly distinguishable from nanocarriers coated with targeting 
antibodies. For experiments involving a therapeutic cargo, mice were injected with 
125I-labeled ASM as a naked counterpart or coated on ∼250 nm antibody-coated 
particles (~0.7 mg ASM/kg body weight, ~1.8 x 1013 particles/kg). Blood samples 
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were collected by penetrating the retro-orbital sinus with a capillary tube (~50-100 
µl collected per sample) at 1, 15, and 30 min after injection, and organs (kidneys, 
spleen, heart, lungs, liver, and brain) were harvested at 30 min following euthanasia 
by cervical dislocation under anesthetic. 125I content and weight of samples were 
determined to estimate the localization ratio (LR) and specificity index (SI). LR 
represents the percent of injected dose accumulated per gram of tissue (%ID/g) 
divided by the %ID/g in blood, to account for differences in organ size and 
circulating nanocarriers.134 The SI is calculated as the LR of targeted formulations 
divided by the LR of non-targeted counterparts (IgG NCs or naked ASM) and 
represents specific targeting.134 These studies complied with IACUC (protocols R-
13-15, R-10-22, R-09-54), University of Maryland regulations, and the Guide for 
Care and Use of Laboratory Animals of the U.S National Institutes of Health. 
 
3.9. Statistics  
Data were calculated as mean ± S.E.M, where statistical significance was determined 
as p≤0.05 by Student’s t-test (2-tailed distribution designed for two samples of equal 
variance (i.e. homoscedastic)). Animal experiments were performed using replicates 
of ≥3 mice per experiment (except for injection of anti-PECAM in control mice or 
anti-ICAM/ASM NCs, anti- TfR/ASM NCs, or free ASM in mice pre-treated with 
LPS where n = 2). Cell culture experiments were performed by using ≥ 105 
cells/well, duplicate wells per condition, and at least 2 repeats. Images were 
randomly taken through the entire coverslip, from which ≥ 15 cells per sample were 
selected randomly and analyzed.  
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Section 4: Results and Discussion   
4.1. Combination Targeting to Multiple Receptors with Similar Functions 
Similar to the interactions of infectious pathogens or leukocytes with multiple cell-
surface markers in nature, combination targeting may enhance accumulation and/or 
precise control of nanocarriers. Targeting nanocarriers to multiple receptors with 
similar function (e.g. involved in a common process or event) was examined in a few 
previous studies mainly in the context of cellular binding of carriers addressed to 
multiple CAMs (see Background: combination targeting).12,23,30,181-187 These 
examples aimed at emulating the adhesive properties of leukocytes by targeting a 
selectin and an Ig-like CAM, which mediate leukocyte rolling and firm adhesion, 
respectively.12,23,30,181-187 Future translation of these strategies, however, requires a 
good understanding of their impact in vivo, where the data are scarce, yet promising. 
For example, targeting iron oxide microparticles to P-selectin/VCAM-1 enhances 
adhesion to aortic root endothelium in a mouse model of atherosclerosis.12 Targeting 
fluorescent microspheres to P-selectin/ICAM-1 enhances adhesion and detection of 
ocular inflammatory disease in the choroidal or retinal microvasculature.182 However, 
to our knowledge the in vivo performance of nanocarriers targeted to multiple CAMs 
has not been examined for submicrometer carriers, a size more amenable for 
intracellular drug delivery applications.3 In addition, combination targeting to CAMs 
involved solely in leukocyte firm adhesion (vs. those encompassing rolling and firm 
adhesion) has never been tested. In addition, the impact of this combination targeting 




many therapeutics require delivery to intracellular compartments. For example, the 
effects of targeting multiple CAMs associated to the same versus different endocytic 
pathways or located in different regions of the plasma membrane have not been 
examined. Finally, the comparative impact of dual vs. triple combination-targeting to 
CAMs is an open question which holds relevance since it better reflects the 
multiplicity of interactions between leukocytes and the endothelium.   
 
 We selected ICAM-1, PECAM-1, and VCAM-1 to test the hypothesis that 
targeting polymer nanocarriers to multiple Ig-like CAMs with similar function 
(namely, firm adhesion and extravasation of leukocytes) modifies nanocarrier 
delivery in terms of binding to cells, endocytosis, and biodistribution. These three 
receptors differ in expression level, cell-surface location, pathological stimulation, 
and/or cell uptake pathway, all of which can affect greatly these parameters. For 
instance, ICAM-1 and VCAM-1 are predominantly located on the luminal surface of 
endothelial cells, while PECAM-1 is enriched at the cell borders.21 In control 
conditions VCAM-1 expression is very low, followed by ICAM-1, and much higher 
expression of PECAM-1.21 VCAM-1 and ICAM-1 expression are enhanced by 
cytokines and other pathological stimuli, while PECAM-1 remains relatively 
stable.21 ICAM-1 and PECAM-1 mediate endocytosis of both nano- and micron-
sized carriers via non-classical CAM-mediated endocytosis,168 whereas VCAM-1 
enables uptake by clathrin-mediated endocytosis,189 which is more size-restrictive 




We first tested binding and endocytosis of nanocarriers single-targeted to ICAM-1, 
PECAM-1, or VCAM-1. Polysytyrene nanospheres were utilized as model polymer 
nanocarriers due to their stability which avoids confounding results of concomitant 
nanocarrier degradation (see Methods). Nanocarriers coated with non-specific IgG or 
with antibodies targeted to PECAM-1 (anti-PECAM NCs), VCAM-1 (anti-VCAM 
NCs), or ICAM-1 (anti-ICAM NCs) displayed  similar valency (∼240-270 
antibodies/NC), size ∼220-330-nm diameter, polydispersity ∼0.2-0.3, and zeta 
potential of ∼-27 - -33 mV, with anti-PECAM NCs somewhat larger in size (Table 
1). The literature values reported for the affinity of antibodies directed to ICAM-1 or 
PECAM-1 ranged from 0.5-8.5 nm,15,205 while the affinity of the antibody directed to 
VCAM-1 is to our knowledge unpublished.  
4.1.2. Binding and endocytosis of antibody-coated nanocarriers single-targeted to 
ICAM-1, PECAM-1, or VCAM-1 









Uncoated NCs 143±18 0.05±0.05 -37.6±1.8  
 Single:    
IgG NCs 238±8.3 0.17±0.02 -27.2±17 240±25 
Anti-ICAM NCs 217±3.5 0.14±0.01 -33.0±3.3 273±37 
Anti-PECAM NCs 333±26 0.26±0.04 -31.0±2.3 250±4.5 
Anti-VCAM NCs 226±10 0.17±0.02 -30.3±0.1 239±22 
Dual:     
Anti-ICAM/ 
PECAM NCs 




Anti-PECAM/                                                    
VCAM NCs 




 Triple:     
Anti-ICAM/PECAM/ 
VCAM NCs 
257±16 0.19±0.03 -32.6±4.9    ICAM:     PECAM:     VCAM: 
    92±0.2      67±20.9       77±18.2 
Data are Mean±S.E.M. Ab = antibody; NC = nanocarrier; PDI = polydispersity; ZP = zeta 




 Binding of anti-ICAM NCs was efficient in control ECs (38-fold over control 
IgG NCs), and increased significantly (85-fold over control IgG NCs) in activated 
ECs (Figure 1). This parallels activation of ICAM-1 expression in disease conditions 
where, for example, endothelial expression is on the order ~105-106 receptors per 
cell in comparison to 104 receptors per cell in physiological conditions.21 Anti-
PECAM NCs displayed higher binding than anti-ICAM NCs in control cells (93-fold 
over IgG NCs) and similar binding to anti-ICAM NCs in activated ECs (110-fold 
over IgG NCs) which paralleled relative expression levels of ICAM-1 and PECAM-
1 in disease conditions.155 In control conditions PECAM-1 expression on 
endothelium is on the order of 106 molecules per cell, which remains fairly stable 
under pathological activation of the endothelium.21 On the other hand, anti-VCAM 
NCs displayed the lowest binding in both control and activated ECs, in agreement 
with comparatively lower expression of VCAM-1 in control vs. inflammatory 
conditions (103 vs. 104-5 receptors per cell, respectively).21,209 
 
 Nanocarriers targeted to ICAM-1, PECAM-1, or VCAM-1 were efficiently 
endocytosed by ECs (Figure 1c-d). The fraction of nanocarriers endocytosed by cells 
relative to the total number of cell-associated nanocarriers (which reflects 












Figure 1. Binding and internalization of nanocarriers targeted to ICAM-1, PECAM-1, or VCAM-1. (a) Fluorescent images of 
nanocarrier binding and internalization tested after incubation for 1 h at 37 °C in TNFα-activated H5V cells, and analyzed by 
fluorescence microscopy to assess the: (b) number of nanocarriers per cell (NCs/cell) and specificity index (SI), (c) percent of 
internalized nanocarriers per cell, and  (d) total nanocarriers internalized per cell for each formulation. Internalized carriers appeared 
green due to single-labeling with FITC, while surface-bound carriers appeared yellow due to FITC + Texas-Red double-labeling. 
Phase-contrast images were used to delimit cell borders (dashed lines).Scale bar is ~ 10 µm. Control IgG NCs are shown as a line in 
(b). Data are mean ± S.E.M. * Compares control vs. TNFα for each formulation, ! compares anti-PECAM NCs to anti-VCAM NCs, # 
compares to anti-ICAM NCs. * ,# represents p < 0.05 by Student’s t-test. 
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The rate of endocytosis in control condition was similar for anti-ICAM NCs and anti-
PECAM NCs with both displaying modestly lower rate than anti-VCAM NCs. Yet, in 
terms of total nanocarrier internalization (Figure 1d), targeting PECAM-1 or ICAM-1 
was similarly more efficient than targeting VCAM-1 in control or activated cells. In 
activated ECs, the internalization rate was similar for anti-ICAM NCs and anti-
VCAM NCs which was higher than for anti-PECAM NCs. This may reflect 
differences in receptor location where receptor-mediated endocytosis is somewhat 
slower via receptors present at cell borders versus receptors present on the cell 
surface. As with modulation of ICAM-1, VCAM-1,  and PECAM-1 expression levels 
in disease, the bulk number of internalized nanocarriers increased significantly in 
activated ECs for anti-ICAM NCs and anti-VCAM NCs, but not anti-PECAM NCs. 
 
We next examined combination-targeting to PECAM-1 and VCAM-1, which differ 
the most with regard to expression level, location, and response to pathology.21 Anti-
PECAM/VCAM NCs had equal amount of anti-PECAM and anti-VCAM on the 
carrier surface (Table 1), with a total added valency similar to that of parent single-
targeted NCs. The size, polydispersity, and zeta potential of anti-PECAM/VCAM 
NCs was also within the range of that observed for parent counterparts and control 
IgG NCs (Table 1).  
4.1.3. Binding and endocytosis of antibody-coated nanocarriers dual-targeted to 




Figure 2. Binding and internalization of nanocarriers targeted to PECAM-1 and/or VCAM-1 in ECs. FITC-labeled nanocarriers were 
incubated for 1 h at 37oC with control or TNFα-activated H5V cells. Cells were then washed, fixed, and surface-bound nanocarriers 
where immunostained with a Texas-Red secondary antibody. Internalized carriers appeared green due to single-labeling with FITC, 
while surface-bound carriers appeared yellow due to FITC + Texas-Red double-labeling.  Images were quantified by fluorescence 
microscopy to determine: (a) the number of nanocarriers per cell and specificity index, (b) the percentage of internalized nanocarriers, 
and (c) total internalized nanocarriers per cell. Data are mean ± S.E.M.  * Compares control vs. TNFα for each formulation, ! 
compares anti-PECAM NCs to anti-VCAM NCs, # compares single-targeted formulation to dual-targeted counterparts. *, #, ! 
represents p < 0.05; by Student’s t-test. 
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 Binding of anti-PECAM/VCAM NCs to control ECs was intermediate 
compared to single-targeted anti-PECAM NCs or anti-VCAM NCs, and this was also 
the case for activated ECs (Figure 2a).  Intermediate binding of anti-PECAM/VCAM 
NCs differs from the behavior previously reported relative to carriers dual-targeted to 
selectins and Ig-like CAMs, which synergistically enhanced binding relative to the 
single-targeted counterparts.23,181,186 It is difficult to compare these strategies because 
most particles used in those studies were in the micrometer-size range versus the 
submicrometer counterparts used here. Yet, in another study E-selectin/ICAM-1 
targeting was also shown to synergistically enhance binding of submicrometer 
liposomes.184 The intermediate level of binding of anti-PECAM/VCAM NCs could 
imply attachment only through PECAM-1, since dual-targeted nanocarriers have 50% 
valency towards the receptor compared to single-targeted nanocarriers. However, 
binding of anti-PECAM/VCAM NCs increased by ∼34% in challenged cells vs. 
control conditions (Figure 2a). This suggests that dual-targeted nanocarriers attach to 
both PECAM-1 and VCAM-1 on the cell surface, since only VCAM-1-targeting had 
shown increased binding of single-targeted nanocarriers to activated cells (Figure 2a). 
Hence, combination-targeting to PECAM-1/VCAM-1 may offer advantages over 
single-targeted formulations: it improves binding compared to VCAM-1-targeting 
and provides reduced attachment to control cells with enhanced binding toward 
diseased ones, compared to PECAM-1-targeting. 
 
 Regarding internalization, anti-PECAM/anti-VCAM NCS were internalized 
efficiently and the internalization rate was not significantly changed under 
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pathological stimulation (Figure 2b). Since PECAM-1 and VCAM-1 are associated 
with CAM-mediated and clathrin-mediated endocytosis, respectively, anti-
PECAM/VCAM NCs may be internalized via both pathways and result in 
intermediate rate of endocytosis compared to single-targeted counterparts. Yet, this 
remains to be determined. In addition, dual targeting modulated total nanocarrier 
uptake as the total number of internalized anti-PECAM/VCAM NCs was intermediate 
with respect to anti-PECAM NCs and anti-VCAM NCs in both control and activated 
conditions. The high endocytosis rates observed for these formulations implies that, 
binding (not rate of endocytosis) affects the capacity of anti-PECAM/VCAM NCs to 
modulate intracellular delivery, and, therefore, tuning targeting plays a key role in 
optimizing these drug delivery systems.   
 
We next tested combination-targeting to ICAM-1 and PECAM-1. These molecules 
have less different levels of expression compared to the previous combination (still 
higher for PECAM-1 but less different in control condition and on the same order of 
magnitude under pathology),21 and they both utilize the same endocytic pathway 
(CAM-mediated endocytosis) for nanocarrier uptake.168 Yet, as in the case of VCAM-
1 vs. PECAM-1, these molecules are also located on the cell lumen vs. border, 
respectively, and are overexpressed vs. unchanged in disease.21 Anti-ICAM/PECAM 
NCs had size, polydispersity, zeta-potential, and total valency within the range of all 
other formulations (Table 1).   
4.1.4. Binding and endocytosis of antibody-coated nanocarriers dual-targeted to 




 Binding of anti-ICAM/PECAM NCs was first compared to anti-ICAM NCs 
and anti-PECAM NCs and as with the PECAM-1/VCAM-1 combination was found 
to be intermediate of single-targeted, parental formulations (Figure 3a). However, 
pathological stimulation with TNFα did not enhance binding of anti-ICAM/PECAM 
NCs to cells and, as a result, binding was lower than parental formulations which was 
a different behavior than observed with the PECAM-1/VCAM-1 combination.  This 
is in agreement with previous studies which have described that, although the level of 
expression and binding of naked anti-ICAM to ECs is markedly increased (∼50-100-
fold) by pathological activation, the level of binding of anti-ICAM NCs changes only 
minimally (∼2-4-fold). This is believed to be due to the fact that, although naked 
antibody can potentially interact with every ICAM-1 molecule on the cell surface, 
steric hindrances posed by bulkier nanocarriers may not allow binding to all available 
receptors.205 An analogous result was observed in the case of polymerosomes 
targeting ICAM-1, which showed similar binding in control versus TNFα 
conditions.186 If this is the case, then binding of anti-ICAM/PECAM NCs is expected 
to respond to activation even less than anti-ICAM NCs, since PECAM-1-targeting 
contributes to binding of anti-ICAM/PECAM NCs and this counterpart is not 




Figure 3. Binding and internalization of nanocarriers targeted to ICAM-1 and/or PECAM-1 in ECs. FITC-labeled nanocarriers were 
incubated for 1 h at 37oC with control or TNFα-activated H5V cells. Cells were then washed, fixed, and surface-bound nanocarriers 
where immunostained with a Texas-Red secondary antibody. Internalized carriers appeared green due to single-labeling with FITC, 
while surface-bound carriers appeared yellow due to FITC + Texas-Red double-labeling. Images were quantified by fluorescence 
microscopy to determine: (a) the number of nanocarriers per cell and specificity index, (b) the percentage of internalized nanocarriers, 
and (c) total internalized nanocarriers per cell. Data are mean ± S.E.M.  * Compares control vs. TNFα for each formulation, ! 
compares anti-PECAM NCs to anti-VCAM NCs, # compares single-targeted formulations to dual-targeted counterparts. *,!,# 
represents p < 0.05 by Student’s t-test. 
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Contrary to anti-PECAM/VCAM NCs, anti-ICAM/PECAM NCs target two receptors 
associated to the same endocytic pathway, CAM-endocytosis. In control and TNFα-
activated cells anti-ICAM/PECAM NCs maintained high internalization of 
nanocarriers, as observed for nanocarriers single-targeted to ICAM-1 or PECAM-1 
(Figure 3b). Dual binding to ICAM-1 and PECAM-1 did not appear to alter the rate 
of endocytosis in control condition. However, unlike anti-ICAM NCs the 
internalization rate of anti-ICAM/PECAM NCs did not change in TNFα-activated 
ECs (Figure 3b). The total uptake of anti-ICAM/PECAM NCs was intermediate of 
anti-ICAM NCs and anti-PECAM NCs in control conditions and lower than both 
parents in TNFα-activated conditions (Figure 3c). This was expected because of the 
similarly high internalization rate of anti-ICAM/PECAM NCs compared with 
parental formulations. As a result and in common with anti-PECAM/VCAM NCs, the 
binding level primarily affected intracellular accumulation rather than differences in 
induction of endocytosis. 
 
We next compared dual targeted formulations with respect to one another and to 
nanocarriers triple-targeted to ICAM-1, PECAM-1, and VCAM-1 (anti-
ICAM/PECAM/VCAM NCs). Binding of anti-ICAM/PECAM NCs was significantly 
higher than anti-PECAM/VCAM NCs in control ECs (1.6-fold, Figure 4a) and 
similar in TNFα-activated ECs (0.93-fold, Figure 4a). This result pairs well with 
greater basal expression of ICAM-1 over VCAM-121 and also with greater binding of 
4.1.5. Binding and endocytosis of antibody-coated nanocarriers dual or triple-targeted 
to ICAM-1, PECAM-1, and/or VCAM-1 
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anti-ICAM NCs over anti-VCAM NCs as shown in Figure 1a. Therefore, the ICAM-
1/PECAM-1 combination displays better targeting to cells, while the PECAM-
1/VCAM-1 combination displays somewhat greater selectivity for diseased cells. 
 
 For both anti-PECAM/VCAM NCs and anti-ICAM/PECAM NCs, 
internalization was highly efficient and unaffected by activation of cells with 
TNFα (Figure 4b). Yet, the rate of endocytosis of anti-ICAM/PECAM NCs was 
somewhat lower than anti-PECAM/VCAM NCs (statistically significant). This is 
counterintuitive since both ICAM-1 and PECAM-1 mediate uptake of carriers by the 
same mechanism, while VCAM-1 and PECAM-1 associate to distinct routes.168,189 
However, it is plausible that simultaneous engagement of two receptors that use the 
same cell machinery for intracellular transport may result in a competition 
phenomenon, leading to decreased endocytosis. Germane to this speculation is that 
sequential stimulation with antibodies to ICAM-1 followed by PECAM-1 has been 
shown to inhibit ICAM-1-induced signaling in ECs, including RhoA activation and 
actin cytoskeletal rearrangement.168,210 The total number of internalized anti-
ICAM/PECAM NCs was greater than anti-PECAM/VCAM NCs in control and 
similar in TNFα-activated ECs (Figure 4c). Therefore, the ICAM-1/PECAM-1 
combination performs better in control conditions where expression of ICAM-1 
exceeds VCAM-1, but in pathophysiologically activated conditions the difference is 
diminished due to activation of VCAM-1 expression. Despite these interesting 
differences the endocytosis rates were high, hence, potential for intracellular delivery 




Figure 4. Binding and internalization of nanocarriers dual- or triple-targeted to ICAM-1, PECAM-1, and/or VCAM-1 in ECs. FITC-
labeled nanocarriers were incubated for 1 h at 37oC with control or TNFα-activated H5V cells. Cells were then washed, fixed, and 
surface-bound nanocarriers where immunostained with a Texas-Red secondary antibody. Internalized carriers appeared green due to 
single-labeling with FITC, while surface-bound carriers appeared yellow due to FITC + Texas-Red double-labeling. Images were 
quantified by fluorescence microscopy to determine: (a) the number of nanocarriers per cell and specificity index, (b) the percentage 
of internalized nanocarriers, and (c) total internalized nanocarriers per cell. Data are mean ± S.E.M.  * Compares control vs. TNFα for 
each formulation, ! compares anti-PECAM NCs to anti-VCAM NCs, # compares single-targeted formulation to dual-targeted 




We next tested nanocarriers triple-targeted to ICAM-1, PECAM-1, and 
VCAM-1 (anti-ICAM/PECAM/VCAM NCs). This is, to the best of our knowledge, 
the first time that triple-CAM targeting is examined.  The size, polydispersity, zeta 
potential, and total valency of these carriers were similar to that of all other 
formulations, with equal split of valency between anti-ICAM, anti-PECAM, and anti-
VCAM (Table 1).  
 
 Under control conditions, binding of triple-CAM targeted nanocarriers to ECs 
was significantly lower compared to either dual-targeted counterpart, including anti-
ICAM/PECAM NCs and anti-PECAM/VCAM NCs (2.3-fold and 1.5-fold lower, 
respectively; Figure 4a).  This is desirable for delivery of therapeutics where it is 
beneficial to selectively target sites of inflammation. It is possible that lowering the 
valency of targeting to ICAM-1 and/or PECAM-1 past a certain threshold (as 
occurred for the valency of triple- vs. dual-targeted counterparts) reduced the binding 
ability of this formulation, just as the binding capacity provided by anti-VCAM NCs 
was reduced in control conditions (in accord with expression). Binding of anti-
ICAM/PECAM/VCAM NCs markedly increased under pathological stimulation, 
reaching a comparable level to anti-ICAM/PECAM NCs and beyond anti-
PECAM/VCAM NCs (Figure 4a).  This suggests that increased expression of ICAM-
1 and/or VCAM-1 in TNFα-activated ECs can compensate for the reduced valency of 
the triple-targeted formulations. Importantly, triple-targeted nanocarriers showed the 
greatest difference in binding between control and TNFα-activated conditions (2.3-
fold, vs. 1.3-fold for anti-PECAM/VCAM NCs or 0.9-fold for anti-ICAM/PECAM 
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NCs), hence, providing the best selectivity toward disease sites without affecting the 
total number of bound nanocarriers per cell (Figure 4a). This finding pairs well with 
selectivity of natural combination-targeting of leukocyte integrins to multiple 
endothelial CAMs during inflammation.211  
 
 Furthermore, endocytosis of anti-ICAM/PECAM/VCAM NCs was 
comparable to anti-PECAM/VCAM NCs and slightly greater than anti-
ICAM/PECAM NCs in both control and TNFα-activated ECs (Figure 4b). As in the 
case of dual-targeted formulations, no change in the endocytic rate of anti-
ICAM/PECAM/VCAM NCs was observed when comparing control to disease 
conditions. This emphasizes the fact that endocytic potential of these formulations 
does not change regardless of absolute binding, at least for the valency ranges used 
here. This also suggests that concomitant attachment to VCAM-1 provided by the 
triple-targeted formulation modestly enhances endocytosis. This is in accord with our 
previous observation comparing dual-targeted carriers indicating that binding to 
CAMs associated to different vs. same endocytic route may be beneficial by relaxing 
the competition for the same cell signaling/machinery involved.  
 
 Overall, these results demonstrate that cell binding of nanocarriers 
functionalized to target multiple CAMs is dependent on the combination of targeted 
receptors utilized, physiological state of the cells, and dual- vs triple- targeted surface 
coating of nanocarriers.  As per intracellular transport, this is highly efficient 
regardless of multiplicity of targeting or patho-physiological conditions, and 
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somewhat endocytic pathway, with only slightly better results when targeting 
different endocytic mechanisms. Hence, the potential for intracellular delivery of 




Differential accumulation of multi-CAM-targeted nanocarriers to cells in culture 
suggests that this surface functionalization strategy may also modify accumulation in 
organs in vivo. Yet, no previous in vivo studies have focused on combination-
targeting to multiple Ig-like CAMs (vs. selectins with Ig-like CAMs) involving 
nanocarriers (vs. micro-scale counterparts). Multi-CAM-targeted materials previously 
examined in vivo include microbubbles targeted to αvβ3-integrin/P-selectin/vascular 
endothelial growth factor receptor 2, which enhanced imaging intensity of MDA-MB-
231 tumors in mice.212 Also, P-selectin/ICAM-1 targeting enhanced adhesion of iron-
oxide microparticles to aortic endothelium in atherosclerosis model mice,12 or 
fluorescent microparticles to retinal and choroidal vessels in rats exposed to 
lipopolysaccharide.182 In addition, one cannot extrapolate the in vivo outcome based 
on results obtained in cell culture.206  
4.1.6. Biodistribution of antibodies vs. antibody-coated nanocarriers single-targeted to 
ICAM-1, PECAM-1, or VCAM-1 
 
 To confirm and comparatively assess targeting of anti-ICAM, anti-PECAM, 
and anti-VCAM in vivo, we first injected these antibodies as naked targeting moieties. 
We focused on brain, lungs, and liver (Figure 5) as examples of central nervous 
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system, peripheral, and clearance organs, respectively, and comprehensive data on the 
biodistribution of these formulations in all organs examined are presented in Table 2. 
Of the three targeting antibodies, anti-PECAM displayed highest accumulation and 
specificity (over IgG) in brain, lungs, liver, and other organs (Figure 5 a,b and Table 
2), which was expected because of much higher levels of PECAM-1 (highest) vs. 
ICAM-1 (intermediate) or VCAM-1 (lowest) expression in endothelium.21 Also in 
agreement with relative levels of expression, anti-ICAM and anti-PECAM displayed 
higher accumulation and specificity than anti-VCAM in the lungs and liver (Figure 5 
a,b), as well as other organs (Table 2). Only PECAM-1-targeting showed specificity 
in the brain (Figure 5 a,b), as anti-ICAM and anti-VCAM both had SI values near to 
1. Higher brain specificity of anti-PECAM vs anti-ICAM appears affected by factors 
beyond expression, as expression levels of PECAM-1 vs. ICAM-1 in brain has been 





Figure 5. Biodistribution of antibodies targeted to ICAM-1, PECAM-1, or VCAM-1 in control mice. Mice were injected 
intravenously with 125I-labeled anti-ICAM, anti-PECAM, or anti-VCAM, and blood and organs were harvested at 30 min after 
injection. (a) The organ-to-blood localization ratio (LR) and (b) the targeted-to-untargeted specificity index (SI) over control IgG are 
shown for the brain, lungs, and liver (see Methods for details). Data are mean ± S.E.M.  ! Compares anti-PECAM to anti-VCAM; # 





 We next compared the biodistribution of nanocarriers single-targeted to ICAM-1, 
PECAM-1, or VCAM-1 after intravenous injection in control mice (Figure 6, Table 2).  The 
greatest accumulation of anti-ICAM NCs was in the lungs (LR ~33), followed by the spleen (LR 
~20), and the liver (LR ~11).  Anti-PECAM NCs accumulated preferentially in the spleen (LR 
~25), followed by the lungs (LR ~16), and the liver (LR ~7).  Finally, anti-VCAM NCs were 
highest in the spleen (LR ~40), followed by the liver (LR ~24)  and the lungs (LR ~4).  Hence, 
the biodistribution of all three carriers differed (Figure 6a, Table 2).  
 
 Accumulation of anti-ICAM NCs was highly specific in lungs and brain, as evidenced by 
17.8-fold and 3.2-fold higher LR of anti-ICAM NCs relative to IgG NCs, respectively (SI, Figure 
6b), while less specificity was observed in other organs (Figure 6b, Table 2).  Anti-PECAM NCs 
had the greatest specificity in the lungs (SI ~8.8), followed by heart (~2.5), brain and kidney (SI 
~2.1), and lower specificity for other organs (Figure 6b, Table 2). In contrast, anti-VCAM NCs 
had greatest specificity in brain (~4.6), followed by kidney (3.0), and spleen (2.6) with lower 





Figure 6. Biodistribution of nanocarriers single-targeted to ICAM-1, PECAM-1, or VCAM-1 in control mice versus lipolysaccharide 
(LPS)-treated mice. Mice were injected intravenously with 125I-labeled anti-ICAM NCs, anti-PECAM NCs, or anti-VCAM NCs, and 
blood and organs were harvested at 30 min after injection. LR (a)  and SI (b) are shown for the brain, lungs, and liver. (c) shows the 
fold-change in SI when utilizing a targeting antibody versus antibody-coated nanocarriers (ΔSI). (d) Shows the fold-change in LR as a 
result of LPS challenge (ΔLR). Data are mean ± S.E.M. ! Compares anti-PECAM NCs to anti-VCAM NCs; # compares each these 




 These results are partially in agreement with cell culture data. For instance, a 
good example reflective of endothelial targeting in vivo is the lungs. This is because 
the pulmonary vasculature constitutes approximately 20-30% of the total endothelial 
surface area in the body, is exposed to relatively low shear stress, and receives the full 
cardiac output.8 In agreement with binding data in cell cultures (Figure 1b), LR and 
SI of anti-VCAM NCs were lower in this organ compared to anti-ICAM NCs and 
anti-PECAM NCs. Yet, in contrast to cell culture, pulmonary accumulation and 
specificity of anti-ICAM NCs were higher compared to anti-PECAM NCs, whereas 
anti-PECAM counterparts displayed greater binding to cells (2.6-fold; Figure 1b). It 
is possible that higher ICAM-1 expression in vivo versus in cell cultures and/or 
reduced access to PECAM-1 located in the cell-cell borders21 due to a tighter 
endothelium in vivo may account for this difference. Indeed, PECAM-1 expression is 
more restricted to the cell-cell border region in ECs exposed to flow conditions 
(reflective of the in vivo situation) than in static cultures.16   
 
 Targeting each molecule with antibodies versus antibody-coated nanocarriers 
greatly and differentially affected organ specificity. Targeting ICAM-1 or VCAM-1 
in nanocarrier format enhanced specificity in all organs with the greatest 
improvement observed in brain (Figure 6c, Table 2). Relatively greater improvement 
in nanocarrier format was observed for anti-VCAM NCs over anti-ICAM NCs, 
perhaps because anti-ICAM targeted organs better than anti-VCAM (Figure 5b). On 
the other hand, specificity declined in all organs for targeted nanocarriers versus free 
antibody addressed to PECAM-1 (Figure 6c, Table 2). This was somewhat expected 
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due to high magnitude of targeting observed for anti-PECAM, likely because of much 
higher PECAM-1 expression, and perhaps also due to steric hindrance effects 
associated with targeting PECAM-1 at cell borders with relatively bulkier 
nanocarriers.  
 
 With regard to mice challenged to mimic a pathological situation (LPS-treated 
mice), we observed enhanced accumulation over control mice although at different 
extent and patterns comparing anti-ICAM NCs, anti-PECAM NCs, and anti-VCAM 
NCs (Figure 6d).  Accumulation of anti-ICAM NCs was enhanced in all organs 
except the brain, with similar improvement in the spleen, heart, and lungs (ΔLR ~2.4, 
2.2, 2.1, respectively; Figure 6c, Table 2).  For anti-PECAM NCs, all organs 
displayed enhanced accumulation except for the spleen, with greatest improvement in 
the lungs, brain, and kidneys (ΔLR ~2.3, 2.3, 2.0). The only enhancement in 
accumulation observed for anti-VCAM NCs was in the lungs (ΔLR ~3.2). This result 
was somewhat unexpected, e.g., PECAM-1 expression is rather unaffected by 
inflammatory mediators, while ICAM-1 and VCAM-1 are markedly enhanced.21 The 
biodistribution pattern of anti-ICAM NCs reflected this, but this was not the case for 
anti-VCAM NCs, except for the lungs. It is possible that the greater accumulation 
differences observed in control lungs between anti-VCAM NCs vs. ICAM-1- or 
PECAM-1-targeted counterparts allowed detection of the corresponding enhancement 
under the inflammatory condition. In the case of anti-PECAM NCs, possible 
redistribution of PECAM-1 from intercellular junctions to the luminal surface in 
diseased mice (as shown in other models)214 may have increased accessibility of 
PECAM-1 relative to control mice. 
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Table 2. Biodistribution of anti-CAM-targeted antibodies and single-targeted nanocarriers  
Ab or  NC      Blood      K idney           Hear t        Spleen                    Lungs                             L iver                                      Brain 
   %ID LR SI          LR          SI             LR               SI                 LR         SI                    LR                  SI                            LR SI 
 Antibody:             
Anti-ICAM 47±2.7 0.6±0.02 2.2±0.1 0.2±0.02 2.0±0.2 0.6±0.04 4.3±0.3 1.8±0.1 12±0.6 0.5±0.03 2.3±0.1 0.02±0.002 1.2±0.1 
Anti-PECAM 11±1.1 2.5±0.3 9.5±1.6 1.9±0.2 18±2.5 3.8±0.1 25±0.9 7.8±1.5 52±14 1.9±0.43 8.2±2.7 0.17±0.01 8.5±0.9 
Anti-VCAM 61±0.4 0.3±0.01 1.3±0.04 0.1±0.01 1.2±0.1 0.7±0.02 4.5±0.2 0.2±0.02 1.1±0.2 0.3±0.01 1.2±0.1 0.02±0.002 1.0±0.1 
 Nanocarr ier :             
Anti-ICAM NCs 6.1±1.3 1.3±0.2 2.7±0.5 0.8±0.2 2.1±0.4 20±4.5 1.3±0.3 32±8.4 18±4.6 11±1.38 1.0±0.1 0.16±0.04 3.2±0.9 
Anti-ICAM NCs 
(LPS+) 
3.3±0.6 1.9±0.5 2.3±0.6 1.7±0.4 3.5±0.8 48±11 1.4±0.3 68±17 15±3.9 16±2.80 0.7±0.1 0.20±0.03 1.4±0.2 
Anti-PECAM NCs 6.6±0.7 1.0±0.1 2.1±0.2 0.9±0.2 2.5±0.6 25±5.4 1.6±0.4 16±3.3 88±1.8 7.3±1.42 0.7±0.1 0.10±0.02 2.1±0.4 
Anti-PECAM NCs 
(LPS+) 
3.5±0.3 2.0±0.3 2.4±0.4 1.5±0.3 3.1±0.6 29±9.6 0.9±0.2 38±3.5 8.4±0.6 15±1.05  0.7±0.03 0.24±0.05 1.7±0.3 
Anti-VCAM NCs 3.5±0.6 1.4±0.3 3.0±0.5 0.7±0.1 2.0±0.4 40±2.2 2.6±0.3 3.8±0.3 2.1±0.4 24±1.61 2.2±0.4 0.23±0.02 4.6±1.1 
Anti-VCAM NCs 
(LPS+) 
2.0±0.2 1.7±0.3 2.0±0.3 1.1±0.2 2.0±0.3 71±12 2.4±0.5 11±2.6 3.1±0.6 48±7.24 2.9±0.6 0.20±0.03 1.4±0.2 
Data are Mean ± S.E.M. %ID = perentage of injected dose; Ab = antibody; NC = nanocarrier; LPS = lipopolysaccharide; LR = 
localization ratio; SI = specificity index. Anti-ICAM was clone YN1, anti-PECAM was clone MEC13, and anti-VCAM was clone 
MK2.   
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We next tested in vivo biodistribution and specificity of nanocarriers displaying 
surface coatings for dual- or triple-CAM targeting (Figure 7). In the spleen and liver, 
the level of accumulation (LR ~16-21 and 9-10, respectively; Figure 7a and Table 3) 
and lack of specificity over control IgG NCs (SI ~1; Figure 7b and Table 3) for all 
three combinations tested (anti-ICAM/PECAM NCs, anti-PECAM/VCAM NCs, and 
anti-ICAM/PECAM/VCAM NCs) was similar to that of parent anti-ICAM NCs and 
anti-PECAM NCs, and markedly reduced compared to anti-VCAM NCs. Hence, 
multi-targeting nanocarriers to ICAM-1 and/or PECAM-1 ruled accumulation and 
resulted in avoidance of these organs relative to VCAM-1, which likely occurred  
primarily via RES-mediated clearance (not targeting the endothelium in these tissues) 
as compared to control IgG NCs.  
4.1.7. Biodistribution of antibody-coated nanocarriers dual- or triple-targeted to 




Figure 7. Biodistribution of nanocarriers dual- or triple-targeted to ICAM-1, PECAM-1, and/or VCAM-1 in control mice versus LPS-
treated mice. Mice were injected intravenously with 125I-labeled anti-PECAM/VCAM NCs, anti-ICAM/PECAM NCs, or anti-
ICAM/PECAM/VCAM NCs, and blood and organs were harvested at 30 min after injection. (a) The organ-to-blood localization ratio 
(LR) and (b) specificity index (SI) over control IgG NCs are shown for the brain, lungs, and liver. (c) Effect of LPS challenge on the 
biodistribution expressed as the fold-change in LR (ΔLR). Data are mean ± S.E.M. ! compares anti-ICAM/PECAM NCs to anti-
PECAM/VCAM NCs;  # compares dual-targeted formulations to the triple-targeted counterpart. * Compares each formulation in 







Table 3. Biodistribution of multi-CAM-targeted nanocarriers 
Nanocarrier Blood   Kidney         Heart      Spleen  Lungs                    Liver                  Brain 




6.2±0.5 0.8±0.1 1.7±0.2 0.5±0.1 1.4±0.3 21±4.5 1.4±0.3 8.1±1.8 4.4±1.0 10±1.4 0.9±0.1 0.1±0.0 1.8±0.3 
Anti-PECAM/ 
VCAM (+LPS) 
3.6±0.1 1.2±0.1 1.5±0.1 0.8±0.0 1.8±0.1 26±3.1 0.8±0.1 22±1.9 4.9±0.4 16±1.3 0.7±0.1 0.2±0.0 1.4±0.1 
Anti-ICAM/ 
PECAM NCs 
5.2±1.0 1.3±0.2 2.7±0.5 1.8±0.3 4.9±0.7 16±4.9 1.1±0.3 71±32 39±17.0 9.7±2.4 0.9±0.2 0.2±0.0 4.4±0.5 
Anti-ICAM/PECAM NCs 
(+LPS) 
2.2±0.3 4.0±0.8 4.8±1.0 4.5±0.2 9.4±0.4 16±1.8 0.5±0.1 266±16 59±3.6 8.7±3.0 0.4±0.1 0.8±0.1 5.6±0.9 
 Triple:             
Anti-ICAM/PECAM/ 
VCAM NCs 
4.5±0.8 1.6±0.5 3.3±1.0 1.8±0.2 4.8±0.4 19±3.9 1.2±0.2 87±34 47±18 9.3±3.2 0.8±0.3 0.2±0.0 4.0±0.7 
Anti-ICAM/PECAM/ 
VCAM NCs (+LPS) 
2.4±0.8 3.7±1.4 4.4±1.7 4.1±1.8 8.6±3.7 73±34 2.2±1.0 102±36 23±7.9 21±7.1 0.9±0.3 0.8±0.3 5.6±2.1 
Anti-ICAM/PECAM/ 
VCAM/ASM NCs 
5.1±0.4 1.5±0.3 3.6±0.9 1.1±0.0 6.4±0.2 23±3.8 50±10 10±2.0 31±7.6 15±2.4 13±2.4 0.2±0.1 6.4±1.6 
Anti-ICAM/PECAM/ 
VCAM/ASM NCs (+LPS) 
2.0±0.2 4.2±0.3 10±0.8 2.7±0.7 15±3.9 81±31 242±93 30±3.3 115±12 36±3.0 64±5.4 0.5±0.0 9.5±0.7 
Data are Mean±S.E.M.. %ID = percentage of injected dose; LR = Localization Ratio; SI = Specificity Index; NCs= Nanocarriers. 
Anti-ICAM was clone YN1, anti-PECAM was clone MEC13, and anti-VCAM was clone MK2.  
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In the lungs of control mice, the accumulation and specificity of dual-targeted 
anti-ICAM/PECAM NCs was significantly increased with respect to single-targeted 
counterparts: LR (and SI as well) was enhanced ~2.2-fold compared to anti-ICAM 
NCs and 4.4-fold compared to anti-PECAM NCs. This was also the case for triple-
targeted nanocarriers, which had slightly higher (22.4%, not significant by t-test) 
accumulation and specificity than anti-ICAM/PECAM formulations. Anti-
PECAM/VCAM NCs showed intermediate pulmonary accumulation and specificity 
compared to single-targeted counterparts. Intermediate targeting by anti-
PECAM/VCAM NCs as compared to parent counterparts and enhanced targeting of 
anti-ICAM/PECAM NCs over anti-PECAM/VCAM NCs closely matched 
observations made in cell culture under control conditions.  Yet, enhanced lung 
targeting of the triple-targeted formulation is opposite to cell culture results. As 
discussed above, this outcome is possibly due to higher expression of pulmonary 
ICAM-1 in vivo.8,204  
 
With regard to other organs, the biodistribution and specificity patterns also 
varied.  In general, targeting to VCAM-1 lowered performance of the dual-targeted 
combination, but not that of triple-targeted nanocarriers (Figure 7a-b, Table 3).  In the 
heart, anti-ICAM/PECAM NCs displayed synergy in that accumulation in this organ 
was considerably better than its single-targeted counterparts, and with similar values 
to triple-targeted formulations (Figure 7 a-b, Table 2-3). In comparison, anti-
PECAM/VCAM NCs showed reduced heart accumulation and specificity, which was 
similar to anti-VCAM NC results and lower than anti-PECAM NCs. In the kidneys, 
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anti-ICAM/PECAM NCs acted similarly to its single-targeted counterparts, anti-
PECAM/VCAM NCs showed decreased performance, and triple-targeted 
nanocarriers improved accumulation and specificity over PECAM-1/VCAM-1, but 
only slightly (not statistically significant) over ICAM-1/PECAM-1-targeted 
formulations.  In the brain, anti-ICAM/PECAM NCs outperformed PECAM-1 and 
was similar to ICAM-1 single-targeted counterparts. Triple-targeted nanocarriers did 
not further improve this enhancement, and anti-PECAM/VCAM formulations 
behaved similarly to anti-PECAM NCs and anti-VCAM NCs. Hence, overall, anti-
ICAM/PECAM NCs performed better than anti-PECAM/VCAM NCs, as with 
binding in cell cultures. Triple-targeted formulations performed closely but somewhat 
better than anti-ICAM/PECAM NCs, which seems to reflect the advantage of 
engaging multiple CAMs used by leukocytes.211  
 
 In LPS-challenged mice, all dual- or triple-targeted combinations enabled 
specific targeting to the kidneys, heart, lung, and brain, as compared to IgG NCs, 
while showing similar accumulation to this control in liver and spleen (Figure 7c and 
Table 3). On top of the already high accumulation in control mice, anti-
ICAM/PECAM NCs displayed even greater accumulation in LPS-treated mice in the 
kidneys, heart, lungs, and brain, with the greatest improvements shown for the last 
two organs (3.7-fold and 3.6-fold enhancement, respectively; Figure 7c and Table 3). 
Anti-PECAM/VCAM NCs showed enhanced accumulation in LPS-activated vs. 
control mice for the kidneys, heart, lungs, liver, and brain, with most acute 
improvements also in the lungs and brain (2.7-fold and 2.2-fold increase, 
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respectively). In general, these results complement well the observation that single-
targeted nanocarriers seemed to respond to inflammatory stimulation in vivo, except 
for the case of anti-VCAM NCs which only showed enhancement by LPS in the 
lungs. Combining targeting to VCAM-1 with targeting to other CAMs seems to 
overcome this caveat and provides for enhanced accumulation in other organs.   
 
 Triple-targeted nanocarriers also showed enhanced accumulation in all organs 
under pathological stimulation except for the lungs, with greatest enhancement in the 
brain and spleen (4.0-fold and 3.9-fold increase), followed by the kidneys and heart 
(2.3-fold and 2.3-fold increase). This result was unexpected, since the lungs represent 
the major targeting organ for single-targeted ICAM-1 or PECAM-1 and considerable 
specific accumulation also occurs with single-targeted VCAM-1 formulations (Figure 
6a,b and Table 2). Also, enhancement under LPS-treatment was observed in this 
organ for both dual-targeted carriers (Figure 7c).  However, triple-targeted 
nanocarriers had shown the highest targeting in the lungs of control mice (Fig. 7a). 
Hence, it is possible that this is already a saturating level of targeting and no further 
enhancement can be achieved with carriers displaying this valency and concentration. 
 
Overall our data show that, with certain differences with regard of organ distribution, 
dual- and triple-targeted formulations enhanced accumulation and specificity of 
nanocarriers in the body under both physiological and pathophysiological contexts. 
Under disease-like conditions, triple-targeted formulations performed closely but 
4.1.8. Biodistribution of a therapeutic cargo by triple-CAM-targeted nanocarriers 
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somewhat better than anti-ICAM/PECAM NCs and clearly superior than anti-
PECAM/VCAM counterparts. Hence, we selected the triple-targeted formulation to 
investigate its potential to improve the biodistribution of a therapeutic cargo in the 
body.   
 
 As an example, we aimed at delivering recombinant acid sphingomyelinase 
(ASM) using the triple-targeted formulation. ASM is a lysosomal enzyme deficient in 
genetic Niemann-Pick disease type A-B (Type A OMIM # 257200, Type B OMIM # 
607616), which is being explored for enzyme replacement therapy via i.v. injection of 
the naked recombinant enzyme.203,215 ASM delivery is necessary throughout the body 
and predominantly in the lungs, brain, and reticulo-endothelial system (liver and 
spleen), which are most severely affected in this disease.5,215 This syndrome also 
associates with inflammation, making CAMs adequate targets for this intervention.215 
 
We labeled ASM with 125I to track the biodistribution of this cargo coupled to 
anti-ICAM/PECAM/VCAM NCs vs. a similar dose of naked ASM intravenously 
injected in mice (Figure 8 and Table 3). Triple-targeted nanocarriers drove 
accumulation of ASM in all organs tested, with greatest LR in the spleen and liver, 
and lowest LR in the brain (Figure 8a and Table 3). Still, this represented a very 
marked enhancement in ASM delivery by nanocarriers over the naked enzyme (SI) 
for all organs tested, including those where LR was relatively low such as the brain, 
where nanocarriers outperformed the naked enzyme by 6.4-fold (Figure 8b and Table 
3). Specific, enhanced delivery by nanocarriers in other organs included 3.6-fold for 
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kidney, 49.9-fold for spleen, 6.4-fold for heart, 30.9-fold for lungs, and 12.7 for liver 
(Figure 8b and Table 3). ASM delivery by anti-ICAM/PECAM/VCAM/ASM NCs 
improved considerably in all organs of LPS-challenged mice, although improvement 
in spleen was not statistically significant (Figure 8a and Table 3). As a result, delivery 
specificity of ASM by nanocarriers over naked enzyme improved by 10.2-fold in 
kidneys, 242-fold in spleen, 15.3-fold in heart, 115-fold in lungs, 63.8-fold in liver, 
and 9.5-fold in brain (Figure 8b and Table 3). Therefore, this strategy seems 
beneficial to improve ASM biodistribution in the body, particularly under 




Figure 8. ASM delivery by nanocarriers triple-targeted to ICAM-1, PECAM-1, and VCAM-1 in control versus LPS-treated mice. 
Mice were injected intravenously with anti-ICAM/PECAM/VCAM/125I- ASM NCs, and blood and organs were harvested at 30 min 
after injection. (a) The organ-to-blood localization ratio (LR) and (b) specificity index (SI) over non-targeted naked ASM are shown 
for the brain, lungs, and liver. Data are mean ± S.E.M. * Compares naked enzyme vs. enzyme coupled to anti-ICAM/PECAM/VCAM 
NCs; # compares control vs. LPS-challenged mice. *,# represents p < 0.05 by Student’s t-test.  
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Enhanced delivery of ASM by nanocarriers triple-targeted to ICAM-1, 
PECAM-1, and VCAM-1 emphasizes the potential of combination-targeting in drug 
delivery and pairs well with other studies reported in the literature. For instance, 
triple-targeting has been explored in the context of cancer, where microbubbles 
targeted to αvβ3-integrin, P-selectin, and vascular endothelial growth factor receptor 2 
showed enhanced cellular binding in vitro and imaging intensity of tumors in vivo.212 
In addition, triple-targeting of tumor endothelial marker 7, folate receptor, and 
PECAM-1 has been investigated as a strategy to enhance uptake of mesoporous 
nanoparticles in both cancer cells and angiogenic blood vessels.7  
 
 
4.1.9. Conclusions  
Targeting nanocarriers to multiple receptors with similar function (e.g. leukocyte 
adhesion and extravasation) can provide advantages for drug delivery, such as 
synergistically enhancing cell binding of nanocarriers targeted to a selectin and an Ig-
like CAM as shown in the literature.12,23,30 In addition, our findings demonstrate that 
targeting nanocarriers to multiple Ig-like CAMs modulates delivery performance 
relative to single-targeted counterparts in a manner which depended on the 
combination and multiplicity of affinity moieties functionalized on the surface of 
nanocarriers, and the physiological state of cells and tissues. PECAM-1/VCAM-1 
targeting improved cellular binding compared to VCAM-1-targeting and slightly 
increased the selectivity toward diseased vs. control cells compared to PECAM-1-
targeting. Anti-ICAM/PECAM NCs provided greater binding than anti-
PECAM/VCAM counterparts, yet were less selective for diseased vs. control cells. 
Triple-targeted nanocarriers appeared promising as they bound activated ECs 
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similarly to anti-ICAM/PECAM NCs, yet displayed superior selectivity over either 
dual-targeted combination. Targeting receptors associated with different endocytosis 
pathways (VCAM-1/PECAM-1) appeared to enhance nanocarrier internalization over 
targeting receptors associated with the same endocytic pathway (ICAM-1//PECAM-
1). Nevertheless, intracellular transport was highly efficient for all conditions tested. 
Hence, the potential for intracellular delivery of these formulations is mostly 
controlled by the level of binding of the functionalized carriers. As in cell culture, 
enhanced targeting of anti-ICAM/PECAM NCs vs. anti-PECAM/VCAM NCs was 
also observed in vivo. Specific targeting of both dual-targeted combinations improved 
further in diseased conditions, suggesting that they can be utilized to enhance delivery 
to sites of disease. Triple-targeted nanocarriers outperformed both double-targeted 
counterparts, greatly enhanced delivery of therapeutic cargo, and showed selectivity 
in certain organs for disease vs. control conditions in vivo, which pairs well with 
natural selectivity of leukocyte integrins engaged in endothelial binding through 
multi-CAM interactions during inflammation.211 Multi-CAM-targeting is a promising 
example of the potential that combination-targeting strategies hold in the context of 










4.2. Combination targeting to multiple receptors with different functions 
 Targeting nanocarriers to multiple receptors with different roles in cellular processes 
(e.g. cell functions) may modulate targeting performance in a distinct manner than 
targeting multiple receptors with similar functions. As discussed in the background, 
this approach is an emerging strategy for drug delivery. However, most prior 
strategies aimed at targeting receptors involved in similar endocytic transport 
pathways, particularly regulated via clathrin-coated pits.13,194,195,216 For example, 
binding to cancer cells of liposomes loaded with the anti-cancer drug doxorubicin was 
enhanced by combination targeting of transferrin receptor and glucose transporter.194 
In addition, pegylated liposomes targeted to transferrin receptor and insulin receptor 
were shown to enable sequential targeting and transport across the blood-brain and 
blood-tumor barriers.13 Only in a couple of examples, the receptors targeted were 
associated with different endocytic mechanisms, yet these studies did not assess 
targeting in vivo and also involved dual targeting of receptors of similar function (e.g. 
cell growth: folate receptor/glucose transporter and folate receptor/epidermal growth 
factor receptor).14,217  
4.2.1. Introduction 
 
 We selected TfR and ICAM-1 to test the hypothesis that targeting multiple 
receptors of unrelated function, regulation, and endocytic mechanism can modify the 
binding, internalization, or biodistribution of polymer nanocarriers. TfR is a 
transmembrane glycoprotein expressed on the surface of many cells, including 
endothelium, and its expression remains relatively stable in disease conditions.6,218 
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TfR enables iron transport across cellular barriers via transcytosis (e.g. in the BBB) 
and into cells by clathrin-mediated endocytosis.219-221 ICAM-1 is also a 
transmembrane glycoprotein expressed on the cell surface of ECs and most other cell 
types, has inducible expression upon activation by inflammatory mediators, and is 
associated with CAM-mediated endocytic transport which enables transport into cells 
and across cell barriers.200,222 Importantly, combination targeting of ICAM-1 and TfR 
may be affected by different valency and size requirements of these receptors for 
binding and endocytosis. However, the targeting performance of these receptors has 
not been assessed comparatively.  
 
To test the impact of the different characteristics of ICAM-1 and TfR on their drug 
targeting performances, we first compared binding of antibodies targeted to ICAM-1 
versus TfR in cell cultures. This was assessed using HUVECs in control or disease 
conditions (TNFα-activation). Fluorescence microscopy analysis showed similar 
antibody binding under control conditions (Figure 9a). However, in agreement with 
ICAM-1 overexpression in disease,200,223 binding increased markedly in ECs pre-
treated with TNFα (15-fold), whereas TfR-binding increased very modestly (1.6-
fold). Consequently, bound anti-ICAM greatly exceeded (by 9.6-fold) anti-TfR under 
pathological stimulation, suggesting that addressing ICAM-1 enhances binding of  
4.2.2. Binding of antibodies vs. antibody-coated nanocarriers or micron-sized carriers 
targeted to ICAM-1 or TfR  




Figure 9. Fluorescence microscopy of antibody binding to ICAM-1 vs. TfR on ECs. (a-b) Control or TNFα-activated HUVECs were 
incubated with anti-ICAM or anti-TfR for 15 min at 37oC. Cells were washed to remove unbound antibody, fixed, stained with FITC-
conjugated goat anti-mouse IgG, and analyzed by fluorescent microscopy to determine the mean fluorescent intensity per cell. Phase-
contrast images were used to delimit cell borders (dashed lines). Scale bar is ~10 µm. Data are mean±S.E.M. * compares control vs. 
TNFα for each target  and # compares ICAM-1 vs. TfR for each condition. *,# represents p < 0.05 by Student’s t-test. 
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 We next compared binding of antibody-coated carriers targeting ICAM-1 
versus TfR (Table 4). Anti-ICAM NCs and anti-TfR NCs displayed similar size 
(∼250 nm), polydispersity (∼0.180), zeta potential (∼−9 mV), and valency (∼275–
300 antibodies/carrier particle). 
 









Anti-ICAM NCs 262±8.6 0.18±0.01 -9.7±0.7 273±37 
Anti-TfR NCs 242±7.1 0.18±0.01 -8.7±0.8 300±31 
Data are mean ± S.E.M. Ab = antibodies; NC = nanocarrier; PDI = polydispersity; Anti-
ICAM was clone R6.5 and anti-TfR was clone T56/14. 
 
 Despite similar antibody binding under control conditions, anti-ICAM carriers 
displayed two-fold enhanced binding to ECs compared with anti-TfR carriers (Figure 
10). For activated ECs, binding of anti-ICAM carriers was enhanced further 
compared to anti-TfR carriers (17.4-fold, Figure 10). Hence, ICAM-1-targeted 
carriers enhanced binding by eight-fold in TNFα-activated conditions, whereas 
binding of TfR-targeted carriers was unchanged compared to control conditions, 
suggesting that targeting nanocarriers to ICAM-1 enhances the binding over TfR in 




Figure 10. Binding of antibody-coated nanocarriers targeted to ICAM-1 or TfR. (a) Fluorescence microscopy of FITC-labeled ∼250 
nm anti-ICAM vs. anti-TfR nanocarriers to control or TNFα-activated HUVECs after 1 h incubation at 37oC. Cells were subsequently 
washed to remove unbound carriers. Phase-contrast images were used to delimit cell borders (dashed lines). Scale bar is ~10 µm. (b) 
Binding was determined as the number of nanocarriers per cell. Data are mean ± S.E.M. * compares control vs. TNFα for each 
target,  and # compares ICAM-1 vs. TfR for each condition.  *,# represents p < 0.05 by Student’s t-test.  
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Since only nanocarriers appeared to bind more efficiently when targeted to 
ICAM-1 as opposed to TfR, we reasoned that steric hindrance effects may influence 
the targeting. Hence, we examined the effect of ligand size and of nanocarrier size on 
the binding of ICAM-1- vs. TfR-targeted nanocarriers. To examine the effect of 
ligand size, ~250 nm carriers were coated antibodies or with smaller affinity moieties, 
namely the ICAM-targeting γ3 peptide or TfR-targeting transferrin (Tf). Binding was 
additionally assessed for carriers of sizes 1µm and 4.5µm to also examine the effect 
of nanocarrier size. We selected the incubation period to be shorter in this case (e.g. 
15 min in Figure 11 versus 1 h in Figure 10), to minimize endocytosis and thus avoid 
confounding effects.  
 
In control ECs, the binding difference between ICAM-1 and TfR-targeted 
carriers was more pronounced using coatings with affinity moieties smaller than in 
the case of antibodies (9.3-fold vs. 0.8-fold, Figure 11b). For larger sized carriers, 
binding of ICAM-1-targeted carriers was greater than TfR-targeted carriers when 
carrier size increased to 1 µm (Figure 11a,c), but similar for even larger, 4.5 µm 
carriers (Figure 11c). In TNFα-activated ECs, binding of ICAM-1 targeted carriers 
remained enhanced vs. TfR-targeted carriers at 1µm size (Figure 11a,c). At 4.5 µm 
carrier size, ICAM-1 targeting also improved binding, although by a smaller margin, 












Figure 11. Binding of ICAM-1 or TfR-targeted nanocarriers using ligands and carriers of different size. Binding was assessed by 
fluorescence (~250 nm carriers) or phase contrast (1µm, 4.5µm carriers) microscopy to determine the number of nanocarriers bound 
per cell in control HUVECs after 15 min incubation at 37oC. (a) Phase contrast micrographs of binding of 1 µm anti-ICAM or anti-
TfR coated carriers (arrows). (b) Binding of FITC-labeled, ~250 nm carriers coated with anti-ICAM or anti-TfR (Ab coat) vs. ICAM-
1 targeting γ3 peptide or TfR-targeting Tf. (c) Binding of anti-ICAM or anti-TfR coated carriers of size ~250 nm, 1 µm, and 4.5 µm in 
control (dashed bars) or TNFα-activated (black bars). Scale bar is ~ 10 µm. Dashed white lines delimit cell borders. Data are mean ± 
S.E.M. * compares control vs. TNFα for each target,   # compares ICAM-1-targeted vs. TfR-targeted carriers, ! compares 1µm or 




 These data suggest a dependency on both proximity of the targeting ligands to 
the nanocarrier surface and a dependency on the size of the carriers due to the effects 
of steric hindrance on binding. ICAM-1 targeting generally appears to enhance EC 
binding over TfR-targeting and this effect became more pronounced in the presence 
of increased steric hindrance. Such an effect may depend on the molecular location of 
the particular epitope targeted by the antibodies used. Anti-ICAM antibodies used in 
this study bind to the two most membrane-distal domains on ICAM-1.200,201 
Unfortunately, this information is not available for anti-TfR antibodies used, yet 
inferring from homology between human and mouse TfR, the antibody used in mice 
may bind a membrane-distal domain of TfR.199 As an example of this concept, it has 
been previously shown that similar carriers directed to a membrane-proximal epitope 
of a related molecule (PECAM-1) lacked binding to cultured ECs vs. carriers targeted 
to membrane-distal epitopes, despite similar binding when presented as free 
counterparts.179 In another study the efficiency of ACE binding to endothelium in 
vivo varied greatly depending on the epitope targeted.196   
 
 Also related to potential steric hindrance for carrier binding, intrinsic features 
of the examined receptors, such as their length and location on the plasmalemma, can 
impact targeting. For example, ICAM-1 extends further from the endothelial lumen 
than TfR (<19 nm vs <9 nm, respectively)224,225 and appears to reside in luminal 
microvilli-like projections226,227 which may be more amenable for engagement by 
targeted carriers. A similar effect was reported for targeting ganglioside GM1 on 
intestinal cells using cholera toxin B as a ligand. While FITC-labeled cholera toxin B 
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(<6 nm) bound cells, conjugation to particles (<29 nm) reduced targeting, and binding 
was totally abolished by increasing particle size (<1.1 μm).228  
 
 ICAM-1 targeting with antibodies or antibody-coated carriers was superior to 
TfR in ECs activated with TNFα. This is likely because ICAM-1 is overexpressed in 
pathological conditions including inflammation, thrombosis, atherosclerosis, 
oxidative stress, and metabolic imbalance.5,229,230 Alternatively, TfR expression 
increases relatively modestly or responds neutrally to different inflammatory 
mediators.231,232 Hence, selecting between these molecules for therapeutic or 
prophylactic interventions depends somewhat on overall and local physiological–
pathological balance. 
 
Since varying the valency of combined-targeting nanocarriers may provide a means 
to optimize nanocarrier internalization, we next compared endocytosis of bivalent 
antibodies and multivalent antibody-coated nanocarriers. Confirming previously 
described (yet not comparative) observations, we found anti-ICAM was poorly 
internalized by ECs compared with anti-TfR (35.6±8.7% vs. 97.7±0.9% uptake; 
Figure 12), even under TNFα-activation where anti-ICAM binding greatly exceeded 
anti-TfR.





Figure 12.  Endothelial endocytosis of antibodies targeted to ICAM-1 vs. TfR. (a) Fluorescence microscopy of endocytosis of 
antibodies targeted to endothelial ICAM-1 vs. TfR. Unbound carriers were removed and surface-bound carriers were stained with a 
Texas-Red secondary IgG. Internalized carriers appear as FITC single-labeled in green, while surface-bound carriers display FITC + 
Texas-Red double-labeled yellow color. Phase-contrast images were used to delimit cell borders (dashed lines). Scale bar is ~10 µm. 
(b) Quantification of uptake of naked anti-ICAM vs. anti-TfR antibodies, assessed after 1 h incubation at 37oC with TNFα-activated 
HUVECs. Data are mean ± S.E.M. # Compares anti-ICAM vs. anti-TfR. # represents p < 0.05 by Student’s t-test. 
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 Contrarily, internalization of ICAM-1-targeted carriers exceeded TfR-targeted 
carriers (Figure 13) in control (83.8±1.7% vs 57.7±2.0% internalization) and disease 
conditions (68.6±0.1% vs. 59.1±0.2% internalization), suggesting more efficient 
carrier uptake by CAM-mediated vs. clathrin-mediated endocytosis. Due to this 
enhanced binding and uptake, the absolute amount of internalized carriers was ~2.6-
fold greater when targeting ICAM-1 vs. TfR: 61.4±3.3 vs. 23.8±1.6 carriers/cell in 
control cells, and 147.0±1.0 vs. 56.1±0.5 carriers/cell in TNFα-activated cells. 
Consequently, although both markers have been shown to support endocytosis and 
also transcytosis,19,168,233 ICAM-1- vs. TfR-mediated vesicular uptake exhibits 
marked differences in that TfR supports better uptake of antibodies and ICAM-1 is 




Figure 13. Endothelial endocytosis of nanocarriers targeted to ICAM-1 vs. TfR. (a) Fluorescence microscopy of endocytosis of 
carriers targeted to endothelial ICAM-1 vs. TfR. Uptake of ∼250 nm FITC-labeled anti-ICAM vs. anti-TfR carriers, assessed after 1 h 
incubation at 37oC in TNFα-activated HUVECs. Unbound carriers were removed and surface-bound carriers were stained with a 
Texas-Red secondary IgG. Internalized carriers appear as FITC single-labeled in green, while surface-bound carriers display FITC + 
Texas-Red, double-labeled yellow color. Phase-contrast images were used to delimit cell borders (dashed lines). Scale bar is ~10 µm. 
(b-c) Internalization was quantified by fluorescence microscopy and expressed as percentage of uptake compared to total cell-
associated carriers (b) or absolute number of carriers internalized per cell (c). Data are mean ± S.E.M. * compares control vs. TNFα 
for each target, and # compares anti-ICAM vs. anti-TfR carriers. *,# represents p < 0.05 by Student’s t-test. 
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To further validate this hypothesis, we then visualized formation of membrane 
engulfment structures around carriers bound to ECs and recruitment of molecular 
partners associated to CAM vs. clathrin pathway. Large 4.5 µm carriers were used to 
facilitate immunofluorescence imaging of NHE1 or clathrin heavy chain enrichment 
at binding sites of anti-ICAM or anti-TfR carriers, respectively. As shown in Figure 
14, ICAM-1 binding lead to rapid (within 15 min) formation of NHE1-enriched 
engulfment structures at the plasmalemma (68.8±3.3% carriers displayed full-ring 
NHE1 clusters around carriers), while engulfment structures enriched in clathrin 
heavy chain were much less apparent for anti-TfR carriers (17.8±3.7% carriers 
displayed full-ring clathrin clusters). This result pairs well with greater vesicular 





Figure 14. Imaging endothelial engulfment of anti-ICAM vs anti-TfR carriers. (a) Microscopy micrographs showing phase contrast 
images (top panels) of ~4.5 µm anti-ICAM vs. anti-TfR carriers after binding for 15 min at 37oC to HUVECs, and fluorescence 
immunostaining (bottom panels) of NHE1 vs. clathrin heavy chain clustering at sites of carrier binding and engulfment (ring-like 
structures indicated with an arrow). Scale bar is ~10 µm. (b) Quantification of the percent of bound carriers showing full ring-like 
engulfment structures enriched in NHE1 or clathrin heavy chain. Data are mean ± S.E.M. # compares anti-ICAM vs. anti-TfR carriers. 
# represents p < 0.05 by Student’s t-test. 
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We next tested the behavior of nanocarriers dually-targeted to ICAM-1 and TfR. As 
shown in Table 5, nanocarriers coated with both anti-ICAM (clone YN1) and anti-
TfR (clone R17) (anti-ICAM/TfR) displayed size, zeta potential, and total antibody 
surface-coating similar to their single-targeted counterparts, with a 1:1 coating-ratio 
of anti-ICAM to anti-TfR.  Literature values of the affinity of antibodies directed to 
ICAM-1 or TfR ranged from 0.5-8.5 nm.205,234 
4.2.4. Binding and endocytosis of nanocarriers dual-targeted to ICAM-1 and TfR  
 
Table 5. Characterization of single- vs. dual-targeted  nanocarriers directed to ICAM and TfR 








 Single:    
Anti-ICAM NCs 228±2.8 0.16±0.03 -9.4±0.5       273±37 
       220±6.3 Anti-TfR NCs 217±5.5 0.16±0.03 -16±1.6 
Anti-TfR/IgG NCs 240±5.0 0.19±0.01 -9.5±0.3 Anti-TfR: 
154±0.9 
IgG:   
136±0.3 
Anti-ICAM/IgG NCs 225±6.6 0.13±0.02 -9.0±0.3 Anti-ICAM:: 
124±25 
 IgG:  
139±2.4 
 Dual:     
Anti-ICAM/TfR  NCs 204±11 0.13±0.003 -12±0.1   Anti-ICAM:  
132±12 
 Anti-TfR:      
145±9.7 
Data are Mean±S.E.M. Ab = antibody; NC = nanocarrier; PDI = polydispersity. Antibody 





Figure 15. Binding of nanocarriers single-targeted or dual-targeted to ICAM-1 and/or TfR. (a-b) Binding was tested after incubation 
for 1 h at 37°C in control H5V cells and analyzed by fluorescence microscopy to assess the mean nanocarriers per cell (NCs/cell) and 
specificity index (SI) for each formulation. Control IgG NCs are represented as a line.  Data are mean ± S.E.M. *Compares fully-
coated anti-TfR NCs to nanocarriers with a 1:1 coating of anti-TfR and control IgG. *,# represents p < 0.05 by Student’s t-test. 
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 Lowering valency of anti-ICAM NCs towards ICAM-1 by half reduced 
binding by 3-fold (Compare anti-ICAM NCs to anti-ICAM/IgG NCs, Figure 15a), 
while binding via TfR improved 1.8-fold as a result of lowered valency. This 
indicated that adjusting the valency of nanocarriers directed to ICAM-1 vs. TfR could 
result in different effects. Varying effects of ligand valency have been observed with 
different receptors previously. For example, multivalency increases binding to cells 
and targeting in vivo in the case of ICAM-1-targeted nanocarriers,205 yet nanocarriers 
targeted to VCAM-1 displayed greater binding to cells using intermediate ligand 
valencies.130 Hence, the valency of targeted nanocarrier formulations needs to be 
evaluated empirically. 
 
 Although binding of nanocarriers via ICAM-1 targeting was significantly 
lowered by reduced valency of anti-ICAM/IgG NCs, binding still remained 
significantly higher than anti-TfR/IgG NCs, indicating that binding at these 
intermediate valency levels was favored by targeting ICAM-1 over TfR (Figure 15a). 
As per the dual-targeted formulation, binding of anti-ICAM/TfR NCs was similar to 
nanocarriers targeting ICAM-1 and higher than nanocarriers targeting TfR, when 
compared to nanocarriers with similar valency of either antibody (anti-ICAM/IgG 
NCs and anti-TfR/IgG NCs, Figure 15b).  
 
 Binding of anti-ICAM/TfR NCs was slightly enhanced (although not 
statistically different) relative to anti-ICAM/IgG NCs and higher than anti-TfR/IgG 
NCs (Figure 15b) which would suggest that a contribution from TfR-targeting may 
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also have occurred. Binding of anti-ICAM/TfR NCs was intermediate relative to anti-
ICAM NCs and anti-TfR NCs which was similar to the pattern observed for 
nanocarriers dual-targeted to CAMs described in the previous section. 
 
 Following binding, we examined the endocytosis of anti-ICAM/TfR NCs.  
Lowering valency of anti-ICAM/NCs resulted in less efficient internalization than the 
full-coated formulation (Figure 16a), suggesting that lower anti-ICAM valency of the 
formulation reduced induction of CAM-endocytosis. On the other hand, endocytosis 
of TfR-targeted carriers remained low independent of valency change (Figure 16a). 
The internalization rate of anti-ICAM/TfR NCs was slightly higher (although not 
significant) than anti-ICAM/IgG NCs and significantly higher than anti-TfR/IgG NCs 
(Figure 16b). Indeed, the total number of nanocarriers internalized was significantly 
greater for anti-ICAM/TfR NCs than anti-ICAM/IgG NCs, suggesting that TfR-
targeting enhanced internalization (Figure 16c). This may be due to greater binding as 
a result of dual ICAM-1- and TfR-targeting, perhaps because of internalization 
 by endocytic receptors associated with different pathways. Interestingly, the behavior 
of anti-ICAM/TfR NCs was similar to the behavior of anti-PECAM/VCAM NCs 
from the previous section, suggesting that this effect may be general to receptors 




Figure 16. Internalization of nanocarriers targeted to ICAM-1 and TfR. Internalization was assessed after 1 h incubation at 37C with 
H5V cells. (a) Effect of valency on internalization of ICAM-1 or TfR-targeted nanocarriers, (b) the percent of internalized 
nanocarriers, and (c) total number of internalized nanocarriers (b) were analyzed by fluorescence microscopy. Data are mean ± S.E.M. 











Figure 17. Biodistribution of anti-ICAM versus anti-TfR antibodies and antibody-coated carriers in mice. (a) Blood levels of 125I-
labeled anti-ICAM vs. anti-TfR or their ∼250 nm carrier counterparts measured at 30 min after i.v. injection in mice, expressed as the 
percentage of the injected dose (%ID). (b-d) Specific tissue accumulation of these formulations compared to control IgG counterparts, 
calculated as the specificity index (SI, see Methods). Data are mean ± S.E.M. * Compares antibodies vs carriers for each target and # 
compares targeting to ICAM-1 vs. TfR for each formulation. * represents p < 0.05 by Student’s t-test. 
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As mentioned above, effective targeting and vesicular transport are crucial elements 
impacting biodistribution of therapeutics. Using radioisotope tracing, we tested 
antibodies and antibody-coated carriers targeted to ICAM-1 vs. TfR (Figure 17 and 
Table 6). As shown in Figure 17a, the circulating blood level of anti-ICAM was 
comparable to anti-TfR at 30 min after injection (46.9±2.7% and 42.1±1.3% of 
injected dose (% ID), and appreciably lower than control IgG (75.5±3.7% ID; data 
not shown), suggesting enhanced accumulation in tissues. Both anti-ICAM and anti-
TfR displayed increase accumulation over control IgG (SI > 1) in all organs with 
similar targeting specificity in liver (SI 2.3±0.1 and 2.4±0.2, respectively; Fig. 17b), 
higher for anti-ICAM vs. anti-TfR in lungs (SI 11.9±0.6 vs. 3.0±0.1; Fig. 17c), while 
anti-TfR showed higher accumulation than anti-ICAM in brain (SI 1.2±0.1 vs. 
1.7±0.2; Figure 17d). 
4.2.5. Biodistribution of antibodies vs. antibody-coated nanocarriers targeted to 
ICAM-1 or TfR 
 
A different behavior was observed for antibody-coated carriers (Table 6).  
Blood levels of anti-ICAM NCs or anti-TfR NCs were considerably lower than naked 
counterparts (Figure 17a). This suggested increased removal from blood and/or 
accumulation in organs, likely due to carrier multivalency. For example, anti-ICAM 
NCs displayed increased accumulation but reduced specificity in RES organs, likely 
resulting from greater non-specific uptake (liver SI decreased from 2.3±0.1 for 
antibodies to 1.0±0.1 for nanocarriers; Figure 17b) and enhanced accumulation in 
peripheral organs and brain: lung SI increased from 11.9±0.6 for antibodies to 
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17.8±4.6 for carriers (Figure 17c) and brain SI increased from 1.2±0.1 to 3.2±0.9 
(Figure 17d). Contrarily, specific tissue accumulation decreased for anti-TfR NCs 
compared to naked antibody counterpart: e.g. liver SI decreased from 2.5±0.2 for 
antibodies to 0.7±0.1 for carriers (Figure 17b), lung SI decreased from 3.0±0.1 to 
0.9±1.2 (Figure 17c), and brain SI decreased from 1.7±0.2 to 1.4±0.3 (Figure 17d). 
Anti-TfR NCs exceeded accumulation over control IgG NCs in brain but not lungs, 
while anti-ICAM NCs displayed specificity in both lungs and brain, with even  better 
performance than anti-TfR in brain (1.9-fold improvement). Hence, results in vivo 
correlate well with cell culture observations of reduced binding and endocytosis of 




Table 6. Biodistribution of nanocarriers targeted to ICAM-1 or TfR 
Ab or NC Blood   Kidney     Heart    Spleen     Lungs     Liver    Brain 
  %ID LR SI      LR  SI  LR    SI  LR     SI          LR SI           LR            SI 
 Antibodies:             
Anti-ICAM 47±2.7 0.6±0.02 2.2±0.09  0.2±0.02 2.0±0.2 0.6±0.04 4.3±0.3 1.8±0.09 12±0.58 0.5±0.03 2.3±0.1  0.02±0.002 1.2±0.1 
Anti-TfR-8D3 42±1.3 0.6±0.05 2.3±0.14  0.1±0.01 1.2±0.1 0.6±0.06 4.2±0.4 0.5±0.02 3.0±0.13 0.6±0.04 2.5±0.2     0.03±0.004 1.7±0.2 
 Single:             
Anti-TfR-8D3 NCs  7.8±1.2 0.3±0.04 0.7±0.09 0.3±0.02 0.8±0.1 38±6.40 2.5±0.4 1.7±0.32 0.9±0.18 8.1±1.1 0.7±0.1  0.07±0.02 1.4±0.3 
Anti-TfR-R17 NCs 6.8±0.7 0.5±0.03 1.1±0.05 0.5±0.06 1.2±0.2 23±3.91 1.5±0.3 2.4±0.33 1.3±0.18 12±1.6 1.1±0.1  0.09±0.02 1.8±0.3 
Anti-TfR-R17/IgG NCs 5.3±0.4 0.5±0.08 1.0±0.16 0.4±0.04 1.0±0.1 18±1.09 1.2±0.1 1.6±0.36 0.9±0.19 13±2.6 1.2±0.2  0.08±0.02 1.7±0.4 
Anti-TfR/ASM NCs 9.8±0.5 0.8±0.10 1.8±0.31 0.5±0.07 2.8±0.5 12±1.85 25±4.9 0.8±0.03 2.4±0.12 5.7±0.4 4.8±0.4  0.11±0.02 2.9±0.5 
Anti-ICAM NCs 6.1±1.3 1.3±0.23 2.7±0.47 0.8±0.16 2.1±0.4 20±4.47 1.3±0.3 33±8.42 18±4.55 11±1.4 1.0±0.1  0.16±0.04 3.2±0.9 
Anti-ICAM/IgG NCs 4.5±0.7 1.0±0.21 2.0±0.44 0.4±0.15 1.2±0.4 38±2.09 2.5±0.1 14±1.99 7.5±1.08 16±2.0 1.5±0.2  0.14±0.05 2.9±1.0 
Anti-ICAM/ASM NCs 4.1±0.4 2.1±0.19 5.1±0.48 1.6±0.24  9.3±1.4 23±3.83 50±8.5 64±11.4 195±36 17±2.4 15±2.1  0.27±0.11 7.2±3.1 
 Dual:             
Anti-ICAM/TfR NCs 4.5±0.7 0.64±0.1 1.31±0.3 0.46±0.1 1.3±0.3 34.8±4.0 2.3±0.3 12.2±4.0 6.62±2.2 19±2.1 1.7±0.2  0.07±0.0 1.4±0.1 
Anti-ICAM/TfR / 
ASM NCs  
7.7±0.4 0.93±0.1 2.26±0.2 0.76±0.1 4.3±0.5 13.2±2.0 28±4.4 3.21±0.3 9.84±1.0 6.4±1.4 5.4±1.2  0.12±0.0 3.1±0.2 
AntiICAM/TfR/ 
ASM NCs (+LPS) 
5.0±0.7   1.31±0.1 3.16±0.3 0.92±0.2   5.3±0.9 15.2±2.8 46±8.3 11.5±1.8 43.7±7.0 13±4.1 23±7.3  0.17±0.0 3.2±0.4 
Data are Mean±S.E.M. %ID = percentage of injected dose; LR = localization ratio; SI = specificity Index; Ab = antibody; NC = 
nanocarrier. Antibody clones were YN1 for anti-ICAM and R1727 (R17, used for Dual) or 8D3 for anti-TfR. 
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Next we tested the biodistribution of anti-ICAM/TfR NCs. In accord with greater 
targeting of nanocarriers to ICAM-1 in cell cultures,208 anti-ICAM NCs had greater 
accumulation and targeting specificity than anti-TfR NCs in the brain and lungs, with 
similar liver uptake (Figure 18 and Table 6). Anti-ICAM/TfR NCs displayed lung 
accumulation and specificity which was intermediate of parental formulations, similar 
to the outcome observed in cell culture.  This may be due to reduced valency of 
dually-targeted nanocarriers toward anti-ICAM, since control anti-ICAM/IgG 
nanocarriers had a similarly reduced pulmonary uptake and reduced targeting in cell 
culture (Figures 15 and 18). However, although lower, pulmonary accumulation of 
anti-TfR NCs was not affected by decreasing valency of this component (compare 
anti-TfR NCs and anti-TfR/IgG NCs in Figure 18). This suggests a stronger 
dependency on antibody surface-density for ICAM-1 vs. TfR targeting, in agreement 
with our finding showing that multivalency associated with nanocarriers vs. naked 
antibodies enhances specific targeting and endocytosis toward ICAM-1, while an 
opposite effect is observed for TfR (Figure 18).208 




Figure 18. Biodistribution of nanocarriers coated with anti-ICAM-1 and anti-TfR in mice. Localization ratio (LR) and specificity 
index (SI) of brain, lungs, and liver are shown in (a) and (b), respectively.  Data are mean ± S.E.M. * Compares anti-TfR NCs to anti-
ICAM NCs; # compares dual-coated nanocarriers (either Ab/IgG or Ab1/Ab2) to their respective single-targeted nanocarriers; % 




Interestingly, brain accumulation and specificity of dually-targeted anti-
ICAM/TfR NCs were comparable to anti-TfR NCs and lower than anti-ICAM NCs 
(Figure 18).  This was independent of valency changes toward anti-ICAM or anti-
TfR, since brain uptake of anti-ICAM/IgG NCs or anti-TfR/IgG NCs was similar to 
their single-targeted counterparts.  For anti-ICAM/TfR NCs, anti-TfR (not anti-
ICAM) ruled brain targeting despite the fact that anti-ICAM NCs accumulate in brain 
better. This also agrees with the observed reduction in  endocytosis of nanocarriers 
via TfR compared to naked antibodies, while the opposite scenario arises for ICAM-1 
targeting (Figure 18).208 Therefore, it is possible that binding of anti-ICAM/TfR NCs 
to TfR reduces or delays uptake by cells despite the presence of anti-ICAM, lowering 
brain accumulation.  This was not observed in lungs, likely due to relatively high 
ICAM-1 expression in this organ vs. the brain.134,204 Liver uptake of anti-ICAM/TfR 
NCs behaved differently, which was slightly greater compared to single-targeted 
formulations.  This may be due to reduced accumulation of these particles in the 
lungs and may also possibly represent increased targeting since liver displays both 
specific accumulation (due to ICAM-1 and TfR expression) as well as non-specific 
clearance. 
 
These data support that exploiting different expression, valency requirements, and 
mechanistic patterns associated with distinct cell-surface receptors, as well as their 
combination targeting, holds potential to modify the biodistribution of drug delivery 
systems. We examined the impact of this approach on the delivery of ASM as a 
model cargo, which as mentioned in the previous section is deficient in Niemann Pick 
4.2.7 Biodistribution of a therapeutic cargo single- or dual-targeted nanocarriers 
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disease types A-B. Then, combination targeting to ICAM-1 and TfR was tested. ASM 
was injected i.v. and targeted via anti-ICAM NCs, anti-TfR NCs, or anti-ICAM/TfR 
NCs compared to naked ASM (as in clinical applications).  
 
 Using similar doses of 125I-ASM, coupling to anti-ICAM NCs or anti-TfR 
NCs significantly lowered blood levels of the circulating enzyme by 30 min post-
injection, i.e. from 29.8±3.8% ID for naked enzyme to 4.1±0.4% ID and 9.8±0.5% ID 
for anti-ICAM/ASM NCs or anti-TfR/ASM NCs, respectively (Figure 19a and Table 
6), suggesting greater removal from circulation and delivery to organs. ASM 
accumulation was enhanced in RES organs, non-RES peripheral organs, and also 
brain for ICAM-1- and TfR-targeted nanocarriers vs. naked counterparts, with greater 
benefit from ICAM-1 targeting. For instance, anti-ICAM/ASM NCs vs. anti-
TfR/ASM NCs displayed liver SI 14.5±2.1 vs 4.8±0.4, lung SI 195.2±36.0 vs. 















Figure 19. Lysosomal enzyme delivery in control mice by ICAM-1- vs. TfR-targeted nanocarriers. (a) Blood levels of 125I-acid 
sphingomyelinase (125I-ASM) injected i.v. in mice as a naked counterpart or coupled to ∼250 nm anti-ICAM NCsvs. anti-TfR NCs, 
measured at 30 min after injection and expressed as the percentage of the injected dose (%ID). (b-d) Specific tissue accumulation of 
anti-ICAM/ASM NCs vs. anti-TfR/ASM NCs compared to naked ASM, calculated as the specificity index (SI). Data are mean ± 
S.E.M. * Compares naked enzyme vs carrier-coupled enzyme for each target and # compares targeting to ICAM-1 vs. TfR. *,# 




 A similar result was observed when LPS was administered via intraperitoneal 
injection prior to the start of the experiment (Figure 20 and Table 6).  In this model, 
ASM delivery using ICAM-1 or TfR-targeted nanocarriers again resulted in enhanced 
clearance from the circulation relative to naked ASM, and also greatly increased 
accumulation in brain lungs and liver (Figure 20). In liver, ASM delivery with TfR-
targeted nanocarriers appeared more similar to ICAM-1-targeted nanocarriers, yet 
appeared less effective in lungs and brain (Figure 20). Therefore, targeting ICAM-1 
or TfR may be valuable for lysosomal enzyme delivery, as previously shown, yet 















Figure 20. Lysosomal enzyme delivery in disease model mice by ICAM-1- vs. TfR-targeted nanocarriers. (a) Blood levels of 125I-acid 
sphingomyelinase (125I-ASM) injected i.v. in LPS-treated mice as a naked counterpart or coupled to ∼250 nm anti-ICAM NCs vs. anti-
TfR NCs measured at 30 min after injection and expressed as the percentage of the injected dose (%ID). (b-d) Specific tissue 
accumulation of anti-ICAM/ASM NCs vs. anti-TfR/ASM NCs compared to naked ASM, calculated as the specificity index (SI). Data 
are mean ± S.E.M. * Compares naked enzyme vs carrier-coupled enzyme for each target and # compares targeting to ICAM-1 vs. TfR. 




 Dually-targeted anti-ICAM/TfR NCs resulted in enhanced ASM accumulation 
and specificity in all three organs compared to naked enzyme (Figure 21).  In 
comparison to single-targeted counterparts, this formulation displayed intermediate 
values of ASM accumulation and specificity in the lungs, and values more similar to 
those corresponding to ASM delivery by anti-TfR NCs in the brain and liver. This is 
similar to the result observed when tracing anti-ICAM/TfR NCs (Figure 18), showing 
paired co-distribution of the carrier targeting counterpart and cargo. As a 
consequence, combined-targeting resulted in a more homogenous, yet still specific 
and enhanced, delivery of ASM through different tissues (Figure 21b), which is 













Figure 21. Delivery of ASM by nanocarriers dual-targeted to ICAM-1 and TfR in control mice.  Localization ratio (LR) and 
specificity index (SI) of brain, liver, and lungs are shown in (a) and (b), respectively.  Data are mean ± S.E.M. * Compares enzyme vs 
nanocarrier-coupled enzyme for each target; # compares targeting between single-targeted nanocarriers; % compares targeting of 
dually-targeted nanocarriers vs. single-targeted counterparts. *,#,% represents p < 0.05 by Student’s t-test. 
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 Furthermore, in mice challenged with LPS, in order to induce inflammation 
typically associated with Niemann-Pick A-B disease and other maladies, dually-
targeted anti-ICAM/TfR NCs improved further ASM accumulation compared to a 
control situation (Figure 22). This pairs well with the fact that ICAM-1 is 
overexpressed under inflammatory conditions and, hence, dual-targeted nanocarriers 
retained the ability to respond to ICAM-1 overexpression.154 Interestingly, this 
phenomenon was observed to a much lesser extent in the case of the brain (e.g. 
comparing the localization ratio and specificity index in Figure 22). This result is in 
accord with our previous observation indicating that TfR targeting seems to rule brain 
addressing (as opposed to the case of lungs) of dually-targeted anti-ICAM/TfR NCs 
(Figure 20). Interestingly, this is despite the expected increase in expression of 
ICAM-1, not TfR, in the brain under inflammatory conditions.213 Hence, the resulting 
biodistribution of dual-targeted nanocarriers cannot be simply explained by their 
reduced valency to each individual receptor (as reported in the previous section), nor 













Figure 22. Delivery of ASM by nanocarriers dual-targeted to ICAM-1 and TfR in control versus inflammatory model mice. 
Localization ratio (LR) and specificity index (SI) of brain, lungs, and liver are shown in (a) and (b), respectively. Data are mean ± 
S.E.M. * Compares naked enzyme vs enzyme coupled to nanocarriers coated with both anti-ICAM and anti-TfR; # compares control 
mice vs mice pre-treated with LPS. *,# represents p < 0.05 by Student’s t-test. 
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While we used a 1:1 ratio of two targeting antibodies on the nanocarrier 
surface, it is likely that further tuning of this parameter may improve organ 
selectivity. For example, selectivity for cancerous versus non-cancerous cells was 
enhanced by optimizing the ratio of folic acid and anti-EGFR antibody coupled to 
liposomes.14  However, as in the case of nanocarriers targeted to multiple receptors 
with similar function, such optimization cannot be predicted, as numerous factors 
relative to both design parameter and physiological features may influence combined 
targeting strategies.  
 
ICAM-1 and TfR have different attributes including function, response to pathology, 
and endocytic activity which has an apparent affect on their use for drug delivery. 
Targeting TfR versus ICAM-1 produced similar results with regard to binding of 
antibodies, yet antibody internalization was clearly favored in the case of TfR-
targeting. On the other hand, ICAM-1 targeting demonstrated certain advantages, 
including binding to cells in inflammatory-like conditions and with relatively larger, 
multivalent NCs, and also in terms of nanocarrier internalization, perhaps due to 
restrictive size of clathrin-coated pits. Differences were also apparent in vivo, as 
naked anti-TfR targeted brain efficiently, yet worsened in the case of NCs, whereas 
ICAM-1 targeting improved when targeted with NCs and appeared best overall for 
targeting brain and lungs. This type of targeting is useful for therapy of lysosomal 
storage disorders, such as Niemann Pick disease types A-B, where brain delivery 
along with multi-organ delivery is needed, and we demonstrated the relative efficacy 




therapy. Therefore, while both TfR and ICAM-1 are beneficial for drug delivery, TfR 
may be more suitable for delivery applications involving small, monovalent drug 
conjugates, whereas ICAM-1 appears preferable for delivery with larger, multivalent 
nanocarriers.   
 Regarding dual targeting of ICAM-1 and TfR, specific binding to cells was 
modified with respect to single-targeting of either receptor, yet was lower than dual-
targeted CAMs from the previous chapter. Thus, targeting multiple receptors with 
similar function may help enhance binding, while either strategy can be used for 
modification. Endocytosis of anti-ICAM/TfR NCs  was enhanced with respect to 
single-targeted formulations and this was also observed with PECAM-1/VCAM-1 
targeted nanocarriers. Both ICAM-1/TfR and PECAM-1/VCAM-1 combinations 
exploit CAM- and clathrin-mediated endocytosis, yet different behaviors may be 
observed when other pathways are combined. ICAM-1 and TfR dual-targeting 
improved accumulation in brain, lungs, and liver in vivo. Accumulation in lungs 
paralleled ICAM-1 targeting, while in brain appeared more similar to TfR-targeted 
nanocarriers, suggesting that dual targeting of ICAM-1 and TfR modified the 
biodistribution relative to single-targeting of either receptor. Delivery of therapeutic 
ASM via ICAM/TfR targeted nanocarriers produced similar results with apparent 
improvement in inflammatory context, suggesting selectivity of this formulation for 
sites of disease as was observed in the case of particular multi-CAM-targeted 
combinations. Therefore, these findings provide new insights which support that 
targeting multiple receptors of different functions with nanocarriers appears a viable 
strategy to modify the binding, endocytosis, and biodistribution of nanocarriers.  
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4.3. Combination Targeting to Multiple Epitopes of the Same Receptor  
Directing nanocarriers to multiple epitopes of the same receptor is an intriguing 
strategy which has never been tested previously. In theory this approach may 
modulate parameters of drug targeting, such as binding to cells, internalization, and 
biodistribution tested in the previous section. For example, binding to one or multiple 
receptor epitopes may alter the conformation of the receptor and consequently affect 
nanocarrier avidity. Alternatively, targeting multiple epitopes may enable binding to 
multiple regions of a single receptor which may also enhance avidity and/or result in 
higher saturation levels by binding fewer receptors per nanocarrier. Empirical 
observations from the literature provide some support for this approach. For example, 
it is known that stimulation of a receptor at one epitope is known to alter activity at 
another epitope. Such is the case for stimulation in vivo of PECAM-1 with an 
antibody, which subsequently enhanced lung accumulation of a second antibody or 
fusion conjugate. In addition, binding, endocytosis, and lysosomal transport of 
PECAM-1-targeted nanocarriers were shown to depend on the epitope targeted.179 
Epitope selection is important for lung accumulation and induced cleavage of anti-
angiotensin converting enzyme,131,196 and brain selectivity of anti- TfR.132  
4.3.1. Introduction 
 
 Therefore, we hypothesized that targeting nanocarriers to multiple epitopes of 
the same receptor can be used as a strategy to modify binding to cells in culture and 
distribution in organs in vivo. To investigate this strategy, we selected the TfR as a 
target receptor due in part to availability of antibodies which are known to have 
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differential targeting in vivo.132 Additionally, as described in the previous section, the 
TfR is widely studied as a receptor for drug delivery applications in the context of 
brain delivery and in cancer.6,132,235   
 
Two monoclonal antibodies were selected to investigate combination targeting to 
multiple epitopes of the same receptor. These antibodies were rat anti-mouse TfR 
clones 8D3 (anti-TfR-8D3) and R17217 (anti-TfR-R17) which have been investigated 
previously in the literature and display distinct biodistribution patterns  when 
administered in vivo.132 
4.3.2. Binding of antibodies vs. antibody-coated nanocarriers targeted to different TfR 
epitopes 
 
We first tested binding of these antibodies in cell culture to verify specific 
targeting over control IgG and to compare the binding toward different TfR epitopes. 
Both anti-TfR-8D3 and anti-TfR-R17 bound ECs specifically as compared to control 
IgG (3.4-fold versus 2.3-fold enhancement, Figure 23a,b), with anti-TfR-8D3 
displaying comparatively greater binding than anti-TfR-R17 (1.5-fold, Figure 23b). 
This verifies that targeting TfR at these respective epitopes results in specific and 




Figure 23. Binding of anti-TfR-8D3 versus anti-TfR-R17 to ECs. (a,b) Binding was tested by immunofluorescence after incubation 
for 1 h at 37°C in control H5V cells, and analyzed by fluorescence microscopy to assess the mean fluorescent intensity (MFI) and 
specificity index (SI, see methods) for each antibody. Phase contrast images were used to delimit cell borders (dashed white lines). 
Scale bar is ~10µm. Line in graph is shown as binding of control IgG.  Data are mean ± S.E.M. *Compares with control IgG, # 




 Since multivalency and size of targeted nanocarriers differ from that of naked 
antibodies, we next assessed the binding of antibody-coated nanocarriers targeted via 
anti-TfR-8D3 or anti-TfR-R17. Nanocarriers coated with anti-TfR-R17 or anti-TfR-
8D3 had similar characteristics, with size ranging between ∼235-265 nm, zeta 
potential from -14.5 to -16 mV, and coating density of 185-220 antibody molecules 
per particle (Table 7). Literature values of the affinity of antibodies directed to TfR 
epitopes 8D3 or R17 ranged from 0.5-2.3 nm.234,236 









 Single:     
Anti-TfR-8D3 NCs 265±28 0.29±0.04 -14.5±3.4 185±2.4 





Anti-TfR-R17 NCs 235±15 0.18±0.04 -15.9±1.6 220±6.27 





 Dual:    




Data are Mean ± S.E.M. Ab = antibody; NC  = Nanocarrier; PDI = polydispersity. Anti-TfR-
8D3 was clone 8d3 and anti-TfR-R17 was clone R17217. 
When each antibody was coated onto nanocarriers and tested under the same 
conditions as for naked antibodies, binding of nanocarriers targeted to the 8D3 
epitope of TfR was again higher than nanocarriers targeted to the R17 epitope (Figure 
24 a-c). Indeed, targeting the 8D3 epitope of the TfR enhanced binding over the R17 
epitope considerably more for nanocarriers than for naked antibodies (8.5-fold versus 
1.5-fold, Figure 24b versus 23b), indicating that epitope 8D3 is more amenable to 














Figure 24. Binding of antibody-coated nanocarriers targeted to TfR epitope 8D3 versus R17. (a-c) Binding was tested after incubation 
for 1 h at 37 °C in control H5V cells, and analyzed by fluorescence microscopy to assess the mean nanocarriers per cell (NCs/cell) and 
specificity index (SI, see methods) for each formulation. Phase contrast images were used to delimit cell borders (dashed white lines). 
Scale bar is ~10µm. Binding of control IgG is shown as a line in b.  Data are mean ± S.E.M. *Compares with control IgG, # compares 




Binding at the R17 epitope was similarly efficient whether used as a naked targeting 
moiety or reformatted into a multivalent NCs, while anti-TfR-8D3 was more efficient 
in the NC format (Figure 24c). 
 
We next tested binding of nanocarriers dually targeted to TfR epitopes R17 and 8D3. 
This is, to the best of our understanding, the first time that dual-targeting to different 
epitopes on the same receptor is examined. Nanocarriers were coated with a 1:1 ratio 
of anti-TfR-R17 and anti-TfR-8D3. To control for the difference in valency relative 
to parental carriers, binding of anti-TfR R17/8D3 NCs was compared to nanocarriers 
coated with a 1:1 ratio of R17 or 8D3 and control IgG. These nanocarriers (anti-TfR-
R17/IgG NCs and anti-TfR-8D3/IgG NCs, respectively) displayed similar size, zeta 
potential, and total antibody surface-coating to anti-TfR-R17/8D3 NCs (Table 7). 
4.3.3. Binding of antibody-coated nanocarriers targeted to multiple TfR epitopes 
 
 Lowering targeting valency to ~ 50% that of parental nanocarriers had 
opposite effects on binding for nanocarriers targeted to epitopes R17 versus 8D3. 
Binding of anti-TfR-R17/IgG NCs was enhanced with respect to fully-coated anti-
TfR-R17 NCs, whereas binding of anti-TfR-8D3 NCs worsened with lower valency 
(Figure 25). As a result, lowering valency nearly doubled binding of nanocarriers 
targeted to the R17 epitope, whereas binding of nanocarriers targeting the 8D3 
epitope was lowered by half. The behavior observed for the 8D3 epitope is intuitive, 
since lowering valency reduces the avidity of NCs for the target epitope. This was 
similar to the behavior of anti-ICAM valency in the previous chapter, where binding 
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was reduced 3-fold as a result of halving the anti-ICAM valency.  Yet, the behavior 
of anti-TfR-R17 NCs with valency is also plausible, as increasing valency past a 
certain threshold has been shown to lead to suboptimal binding for certain 
receptors.130 In terms of binding, lowering valency may cause NCs to occupy fewer 





Figure 25. Effect of antibody valency on binding of antibody-coated nanocarriers targeted to TfR epitope 8D3 versus R17. (a-b) 
Binding was tested after incubation for 1 h at 37 °C in control H5V cells and analyzed by fluorescence microscopy to assess the mean 
number of nanocarriers per cell (NCs/cell) and specificity index (SI) for each formulation. Line in (a,b) indicates binding of control 
IgG.  Data are mean ± S.E.M. *Compares nanocarriers coated with anti-TfR to nanocarriers coated with a 1:1 ratio of  anti-TfR/IgG 




Figure 26. Binding of antibody-coated nanocarriers dually targeted TfR epitopes 8D3 and R17. (a-b) Binding was tested after 
incubation for 1 h at 37 °C in control H5V cells and analyzed by fluorescence microscopy to assess the number of nanocarriers per 
cell (NCs/cell) and specificity index (SI) for each formulation. Phase contrast images were used to delimit cell borders (dashed white 
lines). Scale bar is ~10µm. Line in (b) indicates binding of control IgG. Data are mean ± S.E.M. *Compares with anti-TfR R17/8D3 




Figure 27. Biodistribution of anti-TfR-8D3 versus anti-TfR-R17 in mice. The localization ratio or LR (a) and specificity index orI (b) 
in brain, lungs, and liver were calculated as described (see Methods). Data are mean ± S.E.M. * Compares anti-TfR-8D3 vs. anti-TfR-
R17. * represents p < 0.05 by Student’s t-test. 
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 Binding of anti-TfR-8D3/R17 NCs was intermediate of anti-TfR-R17/IgG 
NCs and anti-TfR-8D3/IgG NCs, respectively (Figure 26).  Dual targeting of TfR 
epitopes R17 and 8D3 with nanocarriers, therefore, modulated cellular binding 
independently of nanocarrier valency. This suggests, for the first time, that targeting 
nanocarriers to multiple epitopes of the same receptor can be utilized as a strategy to 
modify nanocarrier binding, highlighting the rather overlooked relevance of precise 
epitope targeting and its implications in designing effective targeted drug delivery 
systems.   
 
We next tested the biodistribution of anti-TfR-8D3 versus anti-TfR-R17 in vivo. 
These antibodies were injected i.v. as naked 125I-labeled counterparts in mice 
followed by organ analysis after euthanasia. As in previous cases, we focused on the 
brain, lungs, and liver as examples of central nervous system, peripheral, and 
clearance organs, respectively, yet additional data on kidneys, heart, and spleen are 
also provided in accompanying Table 8. As shown in Figure 27, both anti-TfR-8D3 
and anti-TfR-R17 resulted in comparable (Figure 27a) and specific (SI value above 1) 
accumulation in brain (Figure 27b). Yet, they also accumulated considerably and 
specifically in other organs.   
4.3.4. Biodistribution of antibodies vs. antibody-coated nanocarriers targeted to 
different TfR epitopes 
 
 Anti-TfR-8D3 targeted TfR throughout the body more efficiently than anti-
TfR-R17, yet the specificity of this antibody in peripheral organs exceeded its brain 
specificity, which was not observed in the case of anti-TfR-R17.  This is despite the 
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fact that both antibodies have been reported to display similar affinity234,236 and in 
agreement with greater targeting of anti-TfR-8D3 in cell culture (Figure 23). This 
result is also consistent with previous work showing the different biodistribution 
patterns of these antibodies in vivo,132 which may be due to differential accessibility 
of their respective epitope targets, or different presence throughout the body of 
receptor isoforms predominantly exposing these particular epitopes. Indeed, previous 
works have shown differences in reactivity of anti-TfR antibodies to different cell 
lines or tissues in vivo,237,238 and two TfR isoforms displaying distinct post-
translational glycosylations have been reported in mice.239  
 
 Next, we assessed targeting of nanocarriers coated with anti-TfR-8D3 or anti-
TfR-R17. Nanocarriers coated with anti-TfR-R17 or anti-TfR-8D3 both displayed 
increased accumulation in brain, lungs, and liver in comparison to their naked 
antibody counterparts (Figures 28a and 29a).  This result pairs well with enhanced 
avidity of nanocarriers vs naked antibodies due to high valency and also indicates a 
different biodistribution pattern, as in the case of naked antibodies.  Although brain 
still showed specific uptake for both types of nanocarriers (SI > 1), surprisingly, the 
targeting specificity of anti-TfR-8D3 NCs over control IgG NCs was decreased in 
lungs, liver, and slightly in brain in comparison to that of naked anti-TfR-8D3 (Figure 
28b). This was in contrast to anti TfR-R17 NCs, which displayed only decreased 











Figure 28. Biodistribution of anti-TfR-8D3 vs. nanocarriers coated with anti-TfR-8D3.  Localization ratio (LR) and specificity index 
(SI) of brain, lungs, and liver are shown in (a) and (b), respectively. * Compares anti-TfR-8D3 vs. anti-TfR-8D3 NCs. Data are mean 








Figure 29. Biodistribution of anti-TfR-R17 vs. nanocarriers coated with anti-TfR-R17.  (a) Localization ratio (LR) and (b) specificity 
index (SI) of brain, lungs, and liver.  Data are mean ± S.E.M. * Compares anti-TfR-R17 vs. anti-TfR-R17 NCs. * represents p < 0.05 




Table 8. Biodistribution of antibodies and antibody-coated NCs targeted to different TfR epitopes. 
 
Data are Mean±S.E.M.; %ID = percentage of injected dose; LR = Localization Ratio; SI = Specificity Index; Ab = antibody; NC = 





Ab or NC Blood Kidney Spleen      Heart              Lungs  Liver                   Brain 
Antibody: %ID LR SI LR SI LR  SI LR SI   LR   SI LR 
Anti-TfR-R17 
SI 
57±9.7 0.1±0.00 0.5±0.1 0.1±0.00 0.7±0.1 1.1±0.4 7.2±2.8 0.2±0.0 1.3±0.1 0.4±0.0 1.6±0.1 0.03±0.00 1.3±0.2 
Anti-TfR-8D3 42±1.3 0.6±0.00 2.3±0.1 0.1±0.00 1.2±0.1 0.6±0.1 4.2±0.4 0.5±0.0 3.0±0.1 0.6±0.0 2.5±0.2 0.03±0.00 1.7±0.2 
 Single:             
Anti-TfR-R17 NCs 6.8±0.7 0.6±0.00 1.1±0.1 0.5±0.06 1.2±0.2 23±3.9 1.5±0.3 2.4±0.3 1.3±0.2 12±1.6 1.1±0.1 0.09±0.02 1.8±0.3 
Anti-TfR-8D3 NCs 7.8±1.2 0.3±0.00 0.7±0.1 0.3±0.00 0.8±0.1 38±6.4 2.5±0.4 1.7±0.3 0.9±0.2 8.1±1.1 0.7±0.1 0.07±0.02 1.4±0.3 
Anti-TfR-R17/IgG NCs 5.3±0.4 0.5±0.08 1.0±0.1 0.4±0.04 1.0±0.1 18±1.1 1.2±0.1 1.6±0.4 0.9±0.2 13±2.6 1.2±0.2 0.08±0.02 1.7±0.4 
Anti-TfR-8D3/IgG NCs 15±1.3 0.3±0.03 0.7±0.1 0.3±0.05 0.8±0.2 25±5.0 1.6±0.3 0.6±0.0 0.3±0.0 4.0±0.6 0.4±0.1 0.05±0.01 1.0±0.2 
 Dual:             
Anti-TfR-R17/8D3 NCs 11±1.3 0.3±0.03 0.7±0.1 0.3±0.04 0.8±0.1 28±4.4 1.8±0.3 1.3±0.4 0.7±0.2 7.6±1.2 0.7±0.1 0.03±0.00 0.7±0.1 
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 Therefore, it appears that enhanced organ uptake of nanocarriers may be in 
part due to non-specific accumulation. This is in accord with results presented in the 
previous section showing that, despite enhanced valency, anti-TfR NCs pose steric 
hindrances leading to poor binding and suboptimal induction of endocytosis as 
compared to naked antibodies, according to TfR length and natural size restrictions of 
clathrin-coated pits.208 In this situation, it is possible that anti-TfR NCs may bind non-
specifically to Fc receptors in tissues, resulting in low specificity. Also, this effect 
seems to depend on the precise epitope targeted and, consequently, its different 
location and accessibility.  
 
In general, anti-TfR-R17 NCs displayed more robust targeting versus anti-
TfR-8D3 counterparts, as opposed to antibodies. A similar outcome has been 
observed for nanocarriers addressed to different epitopes of PECAM-1, where 
targeting to membrane proximal epitopes resulted in lack of nanocarrier targeting.179 
Greater targeting by anti-TfR-R17 NCs in vivo is opposite to greater targeting by anti-
TfR-8D3 NCs in cell culture, also emphasizing differences in the 
presence/accessibility of their epitopes in different cell types and tissues.132,237-239 
 
We next examined the biodistribution of anti-TfR-R17/8D3 NCs.  Interestingly, 
specific accumulation in organs depended more on the epitope targeted by anti-TfR-
8D3 vs anti-TfR-R17 (Figure 30a). For instance, 50% reduction in valency did not 
impact targeting or specificity by anti-TfR-R17, while a similar reduction negatively 
impacted both parameters in the case of anti-TfR-8D3 (Figure 30a).  




Figure 30. Biodistribution of antibody-coated nanocarriers dual targeted to TfR epitopes 8D3 and R17. (a) LR and (b) SI of brain, 
lungs, and liver are shown in (a) and (b), respectively. Data are mean ± S.E.M. * compares anti-TfR-R17 NCs to anti-TfR-8D3 NCs; # 
compares dual-coated NCs (either Ab/IgG or Ab1/Ab2) to their respective parental, single-targeted NCs; % compares anti-TfR-
R17/8D3 NCs to control Ab/IgG NCs. * ,#,% represents p < 0.05 by Student’s t-test. 
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A 50% reduction in valency also decreased targeting to the anti-TfR 8D3 epitope in 
cell culture, while targeting to the anti-TfR-R17 epitope showed a modest, yet 
statistically significant, improvement. As compared to either parent nanocarrier, 
dually-targeted anti-TfR-R17/8D3 counterparts displayed reduced accumulation in 
brain and comparable pulmonary levels, while liver accumulation was similar to that 
of anti-TfR-8D3 NCs and lower than for anti-TfR-R17 counterparts (Figure 30b). In 
addition, anti-TfR-R17/8D3 NCs lost targeting specificity for all three organs, as their 
SI value fell below 1 (Figure 30c). These effects could in theory be explained by 
reduced overall avidity of dually-targeted nanocarriers toward each independent 
epitope on TfR. Indeed, the specificity of anti-TfR-R17/8D3 in liver and lung had an 
intermediate value compared to that of single-targeted nanocarriers coated at similar 
valencies (anti-TfR-R17/IgG and anti-TfR-8D3/IgG; Figure 30c). However, this was 
not the case for brain, where dually-targeted nanocarriers accumulated below the 
level of both anti-TfR/IgG counterparts. It is possible that binding to two TfR 
epitopes may modify the conformation of the receptor so that exposure and, hence, 
binding to these epitopes may become impaired, displacing the antigen–antibody 
equilibrium toward the unbound form. Conceivable, this phenomenon could impact 
firm binding of dually-targeted nanocarriers at different extents in tissues expressing 
different receptor isoforms,237,238 such as those displaying different post-translational 
glycosylations.239 However, at present, the distribution of these TfR glycoforms in 







Combination targeting to multiple epitopes of the same receptor may aid in enhancing 
or controlling the delivery of nanocarriers, but this hypothesis remained unexplored to 
this point. Selection of anti-TfR 8D3 versus R17 antibodies resulted in differential 
binding to cells and biodistribution in vivo when examined as free antibodies, 
differential response to formatting as targeted nanocarriers versus free antibodies, and 
differential binding when formatted as targeted nanocarries, thus demonstrating the 
importance of epitope selection for optimizing targeting to TfR. Targeting multiple 
TfR epitopes with a single nanocarrier modified binding in cell cultures and 
biodistribution  in vivo, and this constitutes the first evidence that this approach can 
be utilized to control the distribution of nanomedicines. Importantly, modification 
was independent of ligand valency, affirming that the strategy itself accounted for the 
observed binding and biodistribution modifications. Collectively, these results 
highlight the role of precise epitope targeting in drug delivery, the dependency on cell 
and tissue type (apart from other factors), and the unpredictability of these outcomes, 
yet indicating for the first time that combined targeting to multiple epitopes of a 










Section 5. Overall conclusions 
5.1 Summary. 
Despite concerted efforts over the past few decades, precise delivery of 
pharmaceutical agents remains a complex, yet important challenge. Indeed, many 
diseases (common or rare, morbid or mortal, chronic or acute, local or systemic) 
could be treated more effectively by addressing this problem. A promising approach 
in this regard is the development of targeted drug delivery systems which enhance 
accumulation at the intended site and reduce delivery to off-target areas. Yet, 
targeting single cell-surface molecules presents certain limitations such as improved 
but still suboptimal accumulation in many organs/tissues (e.g accumulation in tumors, 
brain, kidneys, heart), due to lack of selective and heterogeneous (spatially and 
temporally) expression of the target molecule at the intended site. Intracellular 
delivery can also be challenging using nanocarriers targeted to single receptors, as 
valency and size requirements of nanocarriers can limit their efficiency. 
Combination-targeting has recently arisen as a strategy to address these issues, yet it 
remains a nascent field with few systematic studies examining effects of this 
approach in general terms, both in cell cultures and in vivo.   
 
 This dissertation provides significant evidence validating the overall 
hypothesis that combination targeting can enhance and/or modify the binding, 
endocytosis, and biodistribution of polymer nanocarriers in different contexts and to 
different extents. With regard to targeting polymer nanocarriers to multiple Ig-like 
CAMs, the binding level and selectivity of multi-CAM targeted nanocarriers for 
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diseased vs. control cells can be modified using different combinations of CAMs or 
by the multiplicity of affinity moieties utilized. Internalization of multi-CAM-targeted 
nanocarriers appears enhanced by targeting receptors associated with different 
endocytic pathways (CAM- and clathrin-mediated endocytosis), rather than targeting 
multiple receptors associated with the same endocytic pathway (CAM-endocytosis). 
Yet, the rate of internalization is efficent regardless of the combination or multiplicity 
of affinity moieties utilized. Multi-CAM-targeted can also modify in vivo 
performance. Dual targeted combinations enhance specificity for organs, but triple-
targeting provides the best performance in vivo of the combinations tested, enabling 
relatively higher specifity in control and particularly diseased tissues of nanocarriers 
and associated therapeutic cargo.  
 
 In the case of multiple receptors with different functions, exemplified by 
ICAM-1 and TFR in this work, combination targeting also appears useful for 
modifying binding, internalization, or biodistribution of polymer nanocarriers. The 
different biological attributes (e.g. function, response to pathology, and endocytic 
activity) of ICAM-1 and TfR affected their drug delivery performance. Whereas 
binding to ICAM or TfR with antibodies is fairly similar, internalization is favored in 
the case of TfR-targeting. However ICAM-1 targeting was favored in terms of 
binding to cells in inflammatory-like conditions, with relatively larger and 
multivalent NCs, and in terms of nanocarrier internalization. Performance in vivo 
indicated that both TfR- and ICAM-1 targeting enhanced accumulation in organs 
where TfR-targeting appeared more effective with free antibodies than targeted 
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nanocarriers, and ICAM-1 targeting improved when targeted with NCs and appeared 
best overall. Dual-targeting of TfR and ICAM-1 modified binding of nanocarriers to 
cells, yet was lower than nanocarriers dual-targeted to CAMs. This affirms that 
targeting receptors of the same or different functions are both viable approaches to 
control nanocarrier binding. Dual-targeting of ICAM-1 and TfR enhanced nanocarrier 
internalization compared with single-targeting of TfR and slightly (although not 
significantly) compared with single-targeting of ICAM-1, which, as observed with 
PECAM-1/VCAM-1 targeting, supports that targeting receptors associated with 
different endocytic pathways may improve nanocarrier internalization. In vivo, 
accumulation of dual-targeted nanocarriers in different organs was ruled by ICAM-1 
(lungs) or TfR (brain), suggesting that targeting multiple receptors with different 
functions and endocytic activity modified the biodistribution and delivery of 
associated therapeutic cargo. 
 
 Finally, we demonstrated for the first time that targeting polymer nanocarriers 
to multiple epitopes of the same receptor may also aid in modulating the delivery of 
nanocarriers. Differential binding of nanocarriers observed when addressed to distinct 
TfR epitopes also occurs with dual targeting of nanocarriers targeted toward TfR 
epitopes with a single nanocarrier and independently of ligand valency. A similar 
result can also be attained in vivo, where differential accumulation and specificity for 
tissues of nanocarriers addressed to distinct TfR epitopes was also demonstrated 
when targeting multiple TfR epitopes, suggesting that combined targeting to multiple 
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epitopes of a single cell-surface receptor may help modify the binding and 
biodistribution of nanomedicines. 
 
 Overall, whether nanocarriers are directed to multiple receptors of similar or 
different functions, or to multiple epitopes of the same receptor, combination 
targeting enhances, decreases, or results in a similar level of targeting to cells and in 
vivo accumulation in organs depending on the combination of receptors or epitopes 
targeted, physiological versus pathological status, and also on the particular target 
organ. Consequently, combination targeting can be utilized to modulate targeting 
performance. Combination targeting also allows modulation of nanocarrier 
internalization whether targeting receptors of similar or different functions, and 
targeting receptors associated with different pathways (CAM- and clathrin-mediated 
endocytosis) seems more favorable than targeting receptors associated with the same 
pathway. In all contexts examined, the modulatory behavior could not be predicted, 
which indicates the necessity of exploring strategies for combination targeting 
experimentally.  
 
5.2. Future Directions 
Although these studies provided relevant insight and affirm that combination 
targeting using the three strategies described may be utilized to modify the binding, 
internalization, and/or biodistribution of nanocarriers, several questions are relevant 
to supplementing and expanding this work. Future studies should examine in more 
depth the effects of combination targeting to receptors with the same versus different 
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physiological  functions. For example, competition studies could verify whether 
multi-targeted formulations bind to more than one of their targets, and to what extent. 
This will provide insight into the relative contribution of each of the targets to 
binding, and also on the binding behavior (synergistic vs. additive). Such a study can 
be performed in cell culture by evaluating nanocarrier binding in the presence of free 
ligands to provide competition for the target receptor. This type of study is also 
possible in vivo, but would likely be more costly due to need for larger amounts of 
ligand (e.g. antibody, which is expensive).  
 
 Another useful experiment would be to evaluate which pathways are induced 
during endocytosis of multi-targeted nanocarriers. Presumably, targeting multiple 
receptors induces the pathways associated with each receptor, yet this is unknown. 
Also, the extent of endocytic activation, uptake kinetics, intracellular route and fate 
may differ when multiple pathways  (or a single pathway via multiple receptors) are 
stimulated. In addition, this type of stimulation may induce novel uncharacterized 
mechanisms of uptake. This study can be done by performing internalization 
experiments in the presence of pharmacological agents or siRNA to inhibit particular 
mechanisms of endocytosis. In vivo, it may be possible to perform such a study by 
employing knockout mouse models which lack proteins critical to particular 
mechanisms of endocytosis, although some of these may not be available due to pre-




 The effect of nanocarrier (size, shape, composition) and ligand (size, valency, 
stiffness) characteristics should also be evaluated to gain more detailed insight in the 
performance of these systems and how they may be optimized for particular 
applications. This type of characterization would be valuable for designing 
combination targeting strategies for particular applications, and it is difficult to 
predict a priori how these parameters will affect the overall delivery performance 
because varying a single parameter can have multiple and opposing effects. For 
example, increasing  the valency of ligands on the nanocarrier surface does not 
necessarily increase avidity for the target receptor (see Background on the role of size 
and valency on nanocarrier performance). This can be examined by titrating these 
parameters in cell cultures or in vivo. In addition, studies examining the cellular 
localization of combined-targeted nanocarriers in vivo would be particulary helpful to 
determine presence in particular tissues and define the application accordingly. This 
could be examined using immunohistochemistry or by energy-dispersive X-ray 
spectroscopy of nanocarriers loaded with an iron core. 
 
 Transport of multi-targeted nanocarriers across cellular barriers remains a 
virtually untouched area in the literature, and could be explored by varying the 
coating ratios of ligands systematically to examine whether the fraction of 
internalized carriers which are transported across cells can be modulated. This may be 
examined using cells cultured on transwell filters, or in vivo using fractionation 
techniques (e.g. capillary depletion) to differentiate accumulation in the vasculature 
vs. the tissue parenchyma. Combination targeting along with more precise control of 
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ligand display on the particular surface by adding ligands to particular “patches” or 
domains may allow for greater control over modulation of targeting performance, and 
as a result more precise adaptation of nanocarriers for particular applications.197,198 
Although much remains to be learned with respect to combination targeting, the 
promise of this approach is considerable as it allows the drug delivery system to be 
endowed with targeting capability by combining properties of existing targets which 





As a result of this dissertation, the following publications have been produced. A 
review paper summarizing the field with insights for future research is planned: 
 
-Papademetriou I, Muro S. Combination-targeting to multiple endothelial cell 
adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of 
drug nanocarriers and their therapeutic cargoes (Submitted). 
 
-Ansar M, Bhowmick T, Papademetriou I, Serrano D, Muro S. Biological 
functionalization of drug delivery carriers to bypass size restrictions of receptor-
mediated endocytosis independently from receptor-targeting (Under revision, ACS 
Nano). 
 
-Papademetriou I, Garnacho C, Muro S. (2013) In vivo performance of nanocarriers 
dually-targeted to epitopes of the same versus different receptors. Biomaterials. 
34(13):3459-66.  
 
-Papademetriou J, Garnacho C, Serrano D, Bhowmick T, Schuchman EH, Muro S. 
(2013) Comparative binding, endocytosis, and biodistribution of antibodies and 
antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 
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